Role of CD40 and Zeb1 in Shaping Normal and Leukemic Bone Marrow Niche by Bassani, Barbara
Open Research Online
The Open University’s repository of research publications
and other research outputs
Role of CD40 and Zeb1 in Shaping Normal and
Leukemic Bone Marrow Niche
Thesis
How to cite:
Bassani, Barbara (2021). Role of CD40 and Zeb1 in Shaping Normal and Leukemic Bone Marrow Niche.
PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2021 Barbara Bassani
https://creativecommons.org/licenses/by-nc-nd/4.0/
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.21954/ou.ro.0001325c
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright













Role of CD40 and Zeb1 in Shaping Normal and 
Leukemic Bone Marrow niche 
 
 
Thesis presented for the degree of Doctor of Philosophy 
The Open University, Milton Keynes (UK) 
 
School of Life, Health and Chemical Sciences 
 
 
Barbara Bassani  












The data presented in this thesis are original, were not previously used for any other 
PhD degree and were originated by me and by the cited below collaborators. During my 
PhD I worked in the Molecular Immunology Unit, Department of Research, at the 
Fondazione IRCCS Istituto Nazionale dei Tumori. My director of studies was Dr. 
Sangaletti Sabina (PhD) and my Supervisor was Dr. Colombo Mario Paolo (PhD).  
 
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC; 
Investigator Grant IG22204). BB is supported by the FIRC-AIRC (Fondazione Italiana 
per la Ricerca sul Cancro) fellowship "Guglielmina Lucatello e Gino Mazzega”.  
 
Immunohistochemistry included in this thesis (Figures 14, 26A,C, 27B, 29C, 31D) were 
performed by Prof. Tripodo Claudio (MD, PhD) and Dr. Alessandro Gulino, Tumor 
Immunology Unit, Department of Health Sciences, University of Palermo. 
Tesi 
Bioinformatic analyses included in this thesis (Figures 13, 24 D, E ) were performed by 
Dr. Simonetti Giorgia, Immuno-Hematology Unit, Istituto Scientifico Romagnolo per lo 
Studio e la Cura dei Tumori (IRST) IRCCS.  
 
Real time analysis of human bone marrow mesenchymal cells (Figure 27A) was 
performed by Dr. Marilena Ciciarello (PhD), Department of Experimental, Diagnostic 
and Specialty Medicine, University of Bologna. 
 
All in vivo experiments were performed with the support of Laura Botti, the technician 
specialized in the animal manipulation and surgery.  
 
The results reported in the 4.2 chapter of this thesis are included in a manuscript 
submitted and published on bioRxiv as a pre-print (doi: 






LIST OF ABBREVIATION 
 
AML - acute myeloid leukemia  
Ang-1 - Angiogenin-1 
APL - acute promyelocytic leukemia  
arg1 - arginase-1  
BM - bone marrow  
BMT - BM transplantation  
BSA - Bovine serum albumine  
CAR - CXCL12-abundant reticular cells  
CBD - p300-P/CAF binding domain  
cDC1 - conventional Type-I DCs  
CDKL2 - cyclin-dependent protein kinase-like 2  
CEBPA - CCAAT/enhancer-binding protein alpha  
CID - CtBP interaction domain  
CKI - cyclin kinase inhibitor  
CLPs - common lymphoid progenitors  
CM - central memory  
CN-AML - Cytogenetically normal AML  
COX-2 - cyclooxygenase-2   
CR - complete remission  
CSCs - cancer stem cells   
DAB - 3,3'-diaminobenzidine 
DC - dendritic cells 
DLBCL - diffuse large B-cell lymphoma  
DMEM - Dulbecco's modified Eagle's medium 
DMSO - Dimethyl Sulfoxide  
DNMT - DNA methyl transferase  
EBF1 - early B-cell factor 1  
ECs - endothelial cells  
EFS - event-free survival  
EM - effector memory  
eMDSC - early stage myeloid derived suppressor cells 
EMT - epithelia-to-mesenchymal transcription  
ER - estrogen receptor 
EVs - extracellular vescicles  
FAB - Franco- American-British  
FBS - fetal bovine serum  
FLT-3 - fms like tyrosine kinase 3  
FOG1 - friend of GATA-1  
GEO- gene expression omnibus 
GEP- gene expression profiling  
GFP - green fluorescence protein  
GM-CSF - granulocyte-macrophage colony-stimulating factor  
 
 III 
GMPs - granulocyte-macrophage progenitors  
GVHD - graft-versus-host disease  
HC - healthy controls  
HDACi - HDAC inhibitors  
HiDAC - high-dose cytarabine  
HIF-1 - hypoxia-inducible factor-1  
HMs - Haematological malignancies  
hMSCs - human MSCs  
HRP - horseradish peroxidase 
HS - heavy smokers 
HSCs - hematopoietic stem cells  
HSPC - Hematopoietic stem and progenitor cell 
i.v. - intravenous 
ICAM - intercellular adhesion molecule  
IDH - isocitrate dehydrogenase  
IDO - indoleamine 2,3-dioxygenase  
IFNs - interferons  
IGF - insulin growth factor  
IHC - Immunohistochestry  
IL - interleukin  
ISCT - International Society of Cellular Therapy  
JAKs - Janus kinases  
JNK - c-Jun-NH2-kinase  
KD - knock-down 
LepR - leptin receptor  
Lin - - Lineage negative cells 
LPS - lipopolysaccharide  
LSD1 - lysine demethylase1  
LSK - Lin−Sca-1+c-Kit+ 
LT-HSC - long-term-hematopoietic stem cells  
LTHSC - long-term HSC 
M-CSF - macrophage colony-stimulating factor  
MCL - mantle cell lymphoma  
MCP-1 - monocyte chemotactic protein 1  
MEM - Minimum Essential Medium  
MHC - major histocompatibility complex  
MLPs - myelo-lymphoid progenitors  
mMSCs - Mouse MSCs  
MOI - multiplicity of infection  
MPPs - multipotent progenitors  
MSCs - Mesenchymal stem cells  
Nes - Nestin 
NG2 - neural/gial antigen 2  
NK - natural killer  
NPM - nucleophosmin  
OPN - osteopontin 
OS - overall survival  
 
 IV 
PanINs - pancreatic intraepithelial lesions  
PARP - poly ADP ribose polymerase  
PBMC - peripheral blood mononuclear cell 
PCAF - P300/CBP-associated factor  
PGE2 - prostaglandin E2  
PI3K - phosphatidylinositol 3-kinase 
qPCR - quantitative polymerase chain reaction 
r/r - relapsed or refractory  
s.c. - subcutaneously 
SCF - Stem cell factor  
Scr - Scramble  
shRNA - short hairpin RNA  
SID - Smad interaction domain  
SMZL - splenic marginal zone lymphoma  
SOCS - suppressor of cytokine signalling  
STAT - signal transducer and activator of transcription  
T-ALL - T-cell acute lymphoblastic leukemia  
TAMs - tumor-associated macrophages  
TBS - tris-buffered saline  
TCGA - Cancer Genome Atlas  
Teff - Teffector  
TET2 - Tet Methylcytosine Dioxygenase 2  
TFs - transcription factors  
TGFβ  - transforming growth factor-β  
THPO - Thrombopoietin 
TKI - tyrosine kinase inhibitors  
TLR - toll like receptor 
TNF - tumor necrosis factor  
TNFR - TNF receptor  
TRAFs - TNFR-associated factors  
Treg - Tregulatory  
VCAM-1 - vascular cell adhesion molecule 1 
VEGF - vascular endothelial growth factor  
VEGFR2-vascular endothelial growth factor receptor 2 
WHO - world health organization 
YAP - Yes-associated protein  







LIST OF ABBREVIATION ................................................................................................ II	
ABSTRACT ........................................................................................................................... 1	
1.	 INTRODUCTION ............................................................................................................ 3	
1.1	Normal haematopoiesis .......................................................................................................... 3	
1.1.1	 Cell-intrinsic factors ................................................................................................................. 3	
1.1.2	 Cell-extrinsic factors ................................................................................................................ 5	
1.2	Myeloid malignancies ............................................................................................................. 5	
1.3	Acute myeloid leukemia (AML) ............................................................................................ 6	
1.3.1	 Pathophysiology and classification .......................................................................................... 7	
1.3.2	 Standard therapy ..................................................................................................................... 10	
1.3. 3 Novel drugs ............................................................................................................................... 11	
1.4	The BM microenvironment in normal hematopoiesis ....................................................... 11	
1.4.1 Osteoblastic niche (endosteal niche) .......................................................................................... 12	
1.4.2 Vascular niche (central niche) ................................................................................................... 13	
1.4.3 Mesenchymal Stem Cells (MSCs) ............................................................................................. 14	
1.5	The BM microenvironment in myeloid malignancies ....................................................... 15	
1.6	Immunomodulatory properties of MSCs ........................................................................... 18	
1.7	AML and immune system .................................................................................................... 19	
1.8	Zeb-1 ...................................................................................................................................... 21	
1.8.1	 Zeb-1 in solid tumours ........................................................................................................... 23	
1.8.2	 Zeb-1 in the immune system .................................................................................................. 25	
1.8.3	 Zeb-1 in leukemia .................................................................................................................. 29	
1.9 CD40 ...................................................................................................................................... 30	
1.9.1 CD40 expression by stromal cells .............................................................................................. 31	
2	 AIM OF THE STUDY ................................................................................................... 33	
3. MATERIALS AND METHODS ..................................................................................... 34	
3.1 Global gene expression profiling (GEP) and bioinformatics ............................................ 34	
3.2 Cell cultures and chemicals ................................................................................................. 37	
3.3 Stable gene-silencing ............................................................................................................. 38	
3.4 Total RNA extraction, reverse transcription, and quantitative polymerase chain 
reaction (qPCR) .......................................................................................................................... 38	
3.5 In vivo murine models and bone marrow analysis ............................................................ 39	
3.6	Immunohistochemistry (IHC) ............................................................................................. 40	
3.7	Metastases quantification ..................................................................................................... 41	
3.8 Immunoblotting .................................................................................................................... 41	
 
 
3.9 Invasion assay ....................................................................................................................... 41	
3.10 Proliferation assay .............................................................................................................. 42	
3.11 In vitro suppression assay .................................................................................................. 42	
3.12 MDSCs and neutrophil isolation from human and mice ................................................ 42	
3.13 Transient silencing of human neutrophils ........................................................................ 43	
3.14 Isolation and culture of murine BM-MSCs ...................................................................... 44	
3.15 Isolation of murine BM-MSCs from lethally irradiated mice ........................................ 44	
3.16 MSC stimulation and treatment with anti-CD40 monoclonal antibody ....................... 44	
3.17 Statistical analysis ............................................................................................................... 45	
4. RESULTS ........................................................................................................................ 46	
4.1 Role of ZEB1 in stroma- and clone-related mechanisms of immunosuppression 
and aggressiveness in acute myeloid leukemia (AML). ........................................................... 46	
4.1.1 Zeb-1 is expressed by human MDSC and neutrophils and correlates with 
immunosuppressive markers ............................................................................................................... 46	
4.1.2 Zeb-1 high levels identify a subgroup of Cytogenetically normal (CN)-AML patients with 
peculiar immune regulatory features. ................................................................................................. 48	
4.1.3 In situ expression of Zeb1 and its correlation with immune regulatory markers in human 
AMLs .................................................................................................................................................. 50	
4.1.4 Zeb-1 expression in murine model of AML and its association with immune markers ............ 52	
4.1.5 Zeb-1 silencing impairs cell-intrinsic immunosuppressive properties of AML blasts .............. 53	
4.1.6. C1498 cells suppress T-cell proliferation via ZEB-1 ............................................................... 55	
4.1.7 Zeb-1 downregulation is associated with the decreased C1498 engraftment within the BM .... 56	
4.1.8 Decreased AML engraftment in mice injected intra-bone with shZEB1 cells is associated 
with the expansion of cytotoxic CD8+ cells ....................................................................................... 58	
4.1.9 Reduced expansion of IL17+ CD3 cells in the BM of mice receiving shZEB1 C1498 cells .... 64	
4.1.10. IL17 promotes C1498 cells proliferation and the expression of stemness markers ............... 66	
4.1.11 Zeb-1 silencing impaired the invasive ability of C1498 without affecting cell 
proliferation ......................................................................................................................................... 68	
4.1.12 Zeb-1 silencing influences the immune-modulatory properties of the stromal 
compartment ....................................................................................................................................... 70	
4.1.13 CD40 is expressed by AML patient-derived MSCs ................................................................ 72	
4.1.14 CD40 stromal expression allow AML take and dissemination ............................................... 73	
4.2 Stromal-derived CD40 regulates bone marrow immune homeostasis ............................ 75	
4.2.1 CD40 stromal expression is induced by pro-inflammatory cytokines ....................................... 75	
4.2.2 CD40 stromal expression instructs BM microenvironment via OX40L ................................... 79	
4.2.3 Altered B-cell lymphopoiesis in the BM is a characteristic of Cd40-KO recipient chimeric 
mice ..................................................................................................................................................... 81	
5.	DISCUSSION ................................................................................................................. 83	






Acute myeloid leukaemia (AML) is an aggressive disease impairing normal 
haematopoiesis. Beyond the genomic landscape and the mutational profile of AML cells, 
increasing evidence demonstrated that bone marrow (BM) microenvironment contributes 
to leukemia development and, in particular, the immunologic landscape is emerging as a 
crucial component of leukemic microenvironment correlating with clinical parameters.  
Leukemic cells express different antigens that are able to activate T-cells triggering an 
anti-leukemia immune response. Thus, we hypothesized that immunogenic leukemia cells 
could set up mechanisms for immune escape including the establishment of 
immunosuppression. To escape from immune recognition leukemic cells could instruct 
neighbouring mesenchymal (MSCs) cells to trigger inhibitory T cell pathways through the 
up-regulation of CD40 or autonomously gain immunosuppressive properties activating 
epithelial to mesenchymal transition-related programs (i.e. ZEB-1). Hence, the aim of this 
study is to evaluate the impact of ZEB-1 expression on AML cell ability to mold an 
immunosuppressive microenvironment. Moreover, we also evaluated the role of CD40 on 
BM-MSCs in shaping the BM tolerogenic niche during leukemia development and in bone 
marrow transplantation. 
 To this aim we firstly analysed the gene expression profile of 61 AML cases that were 
divided in “ZEB1low” and “ZEB1high”. The two groups showed difference between the 
karyotypic features and expressed different levels of immunomodulatory markers. 
Analysis performed using public datasets, showed that ZEB1high patients displayed a worse 
overall survival compared with ZEB1low patients. Immunohistochemistry analysis 
performed on archival BM biopsy showed that ZEB1high cases also showed an expansion 
of CD3+IL-17A+ cells. To unveil the real contribution of ZEB-1 in shaping a BM 
microenvironment, we moved from humans to mouse models. Zeb-1 expressing or 
silenced C1498 murine AML cells were injected intra-bone in immunocompetent mice. 
Mice injected with Zeb-1+ cells showed a higher engraftment compared with mice injected 
with silenced cells. This phenotype correlated with an expansion of Th17 and an increase 
of TIM3+PD1+CD8+ cells within the BM of Zeb-1+ cell injected mice. Molecular studies 
highlighted that Zeb-1 silencing in C1498 induced a significant reduction of Il-6, Tgfβ and 
Il-23, cytokines involved in Th17 differentiation and maintenance. In turn, IL-17A 
promoted AML cell proliferation and aggressiveness in-vitro. Moreover, Zeb-1 silenced 
cells showed a reduced expression of Arg1 that has been reported to negatively affect the 
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activation of CD8+ T cells leading to the increase of cytotoxic CD8+ cells in mice injected 
with silenced C1498. In addition, Zeb-1 was able to up-regulate the expression of Cd40 
and Ido-1 on BM-MSCs. Given the importance of stromal Cd40 expression in sustaining 
the progression of other haematological diseases, we hypothesized that its expression can 
be able to affect AML development. To this end, we injected C1498 cells in Cd40-KO 
mice and we showed that Cd40 deficiency was associated with graft failure. To evaluate 
the immune-regulatory role of stromal Cd40, we performed BM transplantation 
experiments. We observed that Cd40 deficiency leads to the persistent T-cell activation 
with the expansion of CD4+ INF-γ/TNF-α effector T cells and with the parallel depletion 
of regulatory T cells due to an increase production of Ox40l.  
Our results suggest that ZEB1 expression could characterize a group of particularly 
aggressive and chemotherapy resistant AML whose poor outcome is the result of both 







1.1 Normal haematopoiesis  
 
The blood system consists of more than ten different types of cells (lineages), each having 
peculiar functions. Among these cells, leukocytes are involved in immune response, red 
blood cells provide oxygen/carbon dioxide transport and platelets, derived from 
megakaryocytes are crucial players of coagulation and wound healing. The lifetimes of 
the several mature blood cell types range from hours to years. In emergency situations, 
including infections or anemia, blood cell counts rapidly increase and, only after 
recovery, declines back to normal. The process allowing the development of the different 
blood components is termed “hematopoiesis”. Doulatov et al. reported that hematopoiesis 
was postulated for the first time by Maximow in 1909 as a hierarchic process where 
blood cells at the basis derived from common stem cell progenitors that, during 
differentiation, loose their self-renewal and differentiation potential generating terminally 
differentiated mature cells 2.  
In particular, blood cell repertoire arises from hematopoietic stem cells (HSCs) within the 
bone marrow (BM) that give rise to multipotent progenitors (MPPs) retaining multi-
lineage potential. Increasing evidence demonstrated that MPPs first lose their 
erythroid/platelet/megakaryocytic potential and differentiate into myelo-lymphoid 
progenitors (MLPs) characterized by the ability to generate both myeloid and lymphoid 
lineage cells3-5. Downstream of MLPs, we can find the granulocyte-macrophage 
progenitors (GMPs) that give rise to granulocytes, monocytes and myeloid dendritic cells 
and the common lymphoid progenitors (CLPs) that can differentiate into B lymphocytes, 
T lymphocytes and natural killer (NK) cells 5,6. 
Thus, hematopoiesis represents a complex process that is finely tuned by both cell-
intrinsic factors, including transcription factors (TFs) or epigenetics modifier and 
extrinsic factors, i.e. cytokines or molecules released by stromal cells within BM 
microenvironment 6. 
 
1.1.1 Cell-intrinsic factors 
 
The differentiation of HSCs into lineage-committed cells is associated to the expression of 
lineage-specific genes and concomitantly to the repression of those peculiar of another 
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lineage, pointing out that during hematopoiesis cells display relevant changes in their gene 
expression repertoire. These modifications are regulated by TFs, co-factors, chromatin 
modifiers, microRNAs, and other regulatory RNAs 6. A classic example of these 
alterations is represented by the “GATA switch” that occurs before erythropoiesis from 
HSCs. During the differentiation of HSCs into erythroid cells, GATA-1 in a complex with 
friend of GATA-1 (FOG1) directly represses GATA-2 transcription. GATA-1 – FOG1 
complex induces the displacement of GATA-2 at the c-Kit locus, resulting in a chromatin 
rearrangement and in turn, in the down-regulation of c-Kit expression in HSCs 7,8. Laurenti 
et al using transgenic mouse models demonstrated that c-myc and N-myc are two crucial 
TFs regulating HSC proliferation, survival and differentiation, indeed, their combined 
deficiency resulted in a pancytopenia due to the induction of HSC apoptosis 9. Using an in 
vitro culture system, it has been demonstrated that E2A instructs lymphoid cell-fate 
activating the early B-cell factor 1 (EBF1) that antagonize the expression of myeloid-
inducing factors such as pu.1, c/ebpa, and Id2 and parallelly enhancing Pax5 activity, in 
turn promoting B-lineage commitment 10.  
Regarding the epigenetic modifications, it has been shown that DNA methylation is 
associated generally to the up-regulation of differentiation genes, highlighting that DNA 
methyl transferase (DNMT) loss promotes the HSC expansion 11. Indeed, DNMT3a down-
regulation has been demonstrated to decrease self-renewal genes, including Runx1 and 
Gata3 12. Moreover, the concomitant loss of both DNMT3a and DNMT3b in HSCs induces 
the activation of β-catenin pathway leading to the expansion of HSCs 13.  
Polycomb complex protein BMI-1 expression, that is conventionally associated to 
chromatin compaction and decreasing nucleosomal turnover, regulates HSC self-renewal 
in mice through the repression of senescence-related gens, i.e. p16Ink4a, p19Arf, and p53 
14. Another epigenetic modifier, the lysine demethylase1 (LSD1), which belong to the 
histone demethylase family has been reported to promote erythroid differentiation by 
inducing alterations in the GATA-2 locus 15.  
Importantly, all these intrinsic factors, either TFs or epigenetic regulators play a crucial 
role in maintaining the balance between quiescence and proliferation, self-renewal or 
differentiation, survival versus death. Potential alteration of their interplay lead to 







1.1.2 Cell-extrinsic factors 
 
The hematopoietic fate is also regulated by several extrinsic stimuli (i.e. membrane-bound, 
soluble cytokines, or extracellular matrix-associated ligands) that are released by the BM 
microenvironment.  
BM is a very heterogeneous tissue that includes different cell types, such as blood cells, 
mesenchymal cells, osteoblasts, osteoclasts, endothelial cells, reticular cells, fat cells, and 
many other less-defined types. These cells provide numerous signals sustaining HSC self-
renewal and functions. In particular, it has been shown that a multitude of cytokines, along 
with their receptors are important regulators of haematopoiesis 6. As reviewed by Mirantes 
et al, pro-inflammatory cytokines are able to regulate HSC or progenitor cells proliferation 
and differentiation 16. In particular interferons (IFNs) can exert either an anti-proliferative 
activity or promote HSC expansion. In this context, in vitro studies showed that IFN-I 
suppresses HSC quiescence by affecting the transcription of cell cycle regulators, such 
cyclin kinase inhibitor (CKI), Cdkn1c (p57) and Foxo3a and inhibit Notch and TGFβ 
pathways 17. On the contrary, it has been demonstrated that IFN-γ is able to negatively 
regulate HSC proliferation in mice, mainly by inducing the expression of suppressor of 
cytokine signalling (SOCS) 1 in HSCs that reduce thrombopoietin-induced 
phosphorylation of signal transducer and activator of transcription (STAT) 5, one of the 
main positive regulators of HSC self-renwal 18. Moreover, Reynaud et al., using a mouse 
model recapitulating the main features of human chronic myelogenous leukemia 
demonstrated that mmps, expressing high levels of interleukin (IL)-6 receptor, are sensitive 
to Il-6 stimulation, that, in vitro promote myeloid lineage differentiation abrogating 
lymphoid lineage output 19. 
Other cytokines, including IL-1, IL-17 and tumor necrosis factor (TNF) play an important 
role in haematopoiesis. Indeed, IL-1 has been reported to induce myelopoiesis during 
infections 20 and IL-17 positively regulates granulopoiesis and megakaryopoiesis 21. 
Finally, TNF has been shown to suppress HSC activity in vivo 22. 
 
1.2 Myeloid malignancies 
 
Haematological malignancies (HMs) are a heterogeneous group of neoplastic diseases 
involving hematopoietic and lymphoid tissues, with clinical presentation as leukaemia, 
lymphoma, or myeloma. During the last decades, several classifications have been 
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proposed (as reviewed in 23-28). The World Health Organization (WHO) in 2001 developed 
the first worldwide consensus classification on hematological tumors based on their 
clinical, morphologic, biologic, immunophenotypic and genetic features 29. Thereafter, in 
2008 a new classification of HMs was published by WHO in conjunction with the Society 
for Hematopathology and the European Association of Hematopathology 27. The last 
update was in 2016, when the WHO classification was ameliorated based on novel 
information, including genetic mutations recently discovered (as reviewed in 28,30). During 
the last edition of the International Classification of Diseases for Oncology, two distinct 
groups of HMs have been recognized depending on cell lineage myeloid and lymphoid 24-
26. Within each of these groups, a further sub-classification exists according to cell origin, 
levels of maturation, morphology, molecular markers, pathophysiological features, and 
clinical behaviour 31.  
In particular, myeloid malignancies comprise a heterogenous group of clonal 
hematopoietic disorders that arise from the abnormal expansion and impaired 
differentiation affecting myeloid lineages These neoplasms are the result of a multistep 
process involving the accumulation of genetic and epigenetic lesions in HSCs and myeloid 
progenitors 27. Myeloid malignancies can be divided into acute and chronic myeloid 
neoplasms, that can be further classified on the basis of morphology and percentage of 
immature myeloid cells (blasts) in peripheral blood or BM according to Swerdlow et al. 32. 
In particular, 5 categories have been described: acute myeloid leukemia, 
myeloproliferative neoplasms, myelodysplastic syndrome, 
myelodysplastic/myeloproliferative neoplasms, and un-known myeloid neoplasms. 
 
1.3 Acute myeloid leukemia (AML)  
 
Acute myeloid leukemia (AML) is a clonal disorder resulting from the neoplastic 
transformation of HSCs or progenitor cells that lose the ability to differentiate leading to 
the aberrant accumulation of immature myeloid cells within the BM. It is the most 
common form of leukemia accounting for 80% of all cases in the category of adult acute 
leukemia 33. GLOBOCAN estimates that the worldwide incidence of AML for 2012 was 
4.7 new cases per 100,000 inhabitants per year in Europe and the United States, with a 5-
year prevalence of 1.5% and a Male:Female ratio of ~1.4 34. 
Clinically, it is a heterogenous disease with an unclear etiology. It has been reported that 
several events contribute to the AML development, including environmental, 
socioeconomic, epigenetic and genetic factors 35. Moreover, even if in the majority of 
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cases appears as a de novo neoplasm, in some cases, AML can be the consequence of prior 
cytotoxic therapies with intercalating drugs or radiation 36. The diagnosis of AML is 
defined by the presence of more than 20% of myeloid blasts in the bone marrow.  
 
1.3.1 Pathophysiology and classification 
 
Chromosomal abnormalities can be observed in the 55% of the adult and at least in the 
70% of childhood AML cases 37. Well-characterized chromosomal translocations, 
including the t(8:21) in core-binding factor AML (CBF-AML) or the t(15:17) in acute 
promyelocytic leukemia (APL) lead to the generation of chimeric proteins, the RUNX1-
RUNX1T1 and the PML-RARA, respectively 37. In addition to chromosomal 
rearrangements, also genetic mutations have been recognized in more than 97% of cases 38. 
In vivo studies contributed to the development of the “two-hit” model of leukemogenesis. 
Accordingly, class I mutations, i.e. internal tandem duplications (fms like tyrosine kinase 3 
(FLT-3) FLT3-ITD), K/NRAS, TP53 and c-KIT occur with class II mutations, including 
nucleophosmin (NPM)1 and CCAAT/enhancer-binding protein alpha (CEBPA) 39. 
Recently, also alterations in epigenetic regulators (DNMT3A, Tet Methylcytosine 
Dioxygenase 2 (TET2), and isocitrate dehydrogenase (IDH) 1 and 2, have been proposed 
as a third class of mutations able to effect cellular differentiation and proliferation 39.  
Previously, AMLs classification was mainly based on the morphological and 
immunohistochemical characteristic of leukemic cells observed in the patients’ BM and in 
their peripheral blood. The first comprehensive classification system of AML was 
developed in 1976 by the Cooperative Group Franco- American-British (FAB) (reviewed 
in 37). According to these directives, AML were divided into eight subtypes (M0-M7) 
based on AML cell type from which AML originates (Figure 1).  
Introduction 
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Can resemble LLA-L2 blasts. Medium-sized




Medium-sized blasts with high nucleo:cytoplasm (n:c)
ratio, rounded nuclei with immature, dispersed chromatin
with one or more prominent nucleoli. Blasts can show
fine azurophilic granulation or isolated Auer rods in
the cytoplasm in 5% to 10% of cases
Morphology:
Small to medium-sized blasts with high nucleo:
cytoplasm (n:c) ratio and rounded nuclei sometimes
located in a corner of the cytoplasm. The nucleus
shows dispersed, immature chromatin with one or more
nucleoli. The cytoplasm is basophilic and can contain
traces of primary azurophilic granulation or isolated 
Auer rods.
Morphology:
Abundant, intensely azurophilic granulation.
The nucleus is usually monocytic in appearance
(reniform) and is either irregular or bilobed with a
deep cleft. Scarcely basophilic cytoplasm due to the
proliferation of azurophilic granulation. Some atypical
promyelocytes also contain elongated or splinter-
shaped crystalline cytoplasmic inclusions specific to
this type of leukaemia.These usually form clumps,
but differ from Auer rods in that they show a tubular

























Figure  3  French-American-British  (FAB)  classification  of  acute  myeloblastic  leukaemia.  FAB  classification  of  acute  myeloblastic
leukaemia.
FAB  classification  of  acute  myeloblastic  leukaemia
Figs.  3 and  4 show  the immunophenotype  and  morphology  of
acute  myeloblastic  leukaemias  (AML),  together  with  micro-
scope  images  and  a brief  summary.9,11,12
M0 Acute  myeloblastic  leukaemia
Myeloblastic  leukaemia  with  minimal  differentiation,  or
M0-AML,  is  particularly  difficult  to  diagnose  from  the mor-
phological  point of  view  because  the  blasts  present  both
Morphology  of leukaemias  111






Highly immature, polymorphic blasts. The nucleus is
eccentric with dispersed, reticulated chromatin and
1-3 prominent nucleoli. The cytoplasm is non-granular,
basophilic, and very similar in appearance to platelets,
with pseudopods or granulations. Micromegakaryocytes
and fragments of megakarioblasts are seen in peripheral
blood (giant platelets, some highly degranulated).
Immunophenotype
•CD41 + 











•CD33 +   







M5a acute monoblastic leukaemia:
Large blasts with rounded nucleus and dispersed, 
immature chromatin (1-3 nucleoli) and moderately large
and intensely basophilic cytoplasm. The cytoplasm may 
show some Auer rods and/or prolongations 
and granulations.
M5b acute monocytic leukaemia
Promonocytes have a rounded or kidney-shaped
nucleus with a less basophilic cytoplasm that is
more highly granulated than monoblasts and contains
some vacuoles. A findings of erythrophagocytosis
together with monocytic blasts suggests a t(8;16)
translocation.
M6a erythroid leukaemia with proliferation of mixed blasts:
Over 50% erythroid precursors and around 30% myeloblasts.
Morphology of erythrocytes in peripheral blood is greatly changed, 
with schistocytes, “pincered” or mushroom-shaped cells, 
and spiculated echinocyte and acanthocyte cells.
M6b pure erythroid leukaemia:
Erythroids make up 80% of bone marrow
cells, with less than 3% myeloid cells.
Erythrocytes in peripheral blood consist
of macrocytes, basophilic stippling,
Howell-Jolly bodies or Cabot rings.
 Morphology:
Large blasts, moderate nucleo:cytoplasm
(n:c) ratio and variable basophilia. The
nucleus may be rounded, kidney-shaped 












•CD68 +   




Figure  4  French-American-British  (FAB)  classification  of  acute  myeloblastic  leukaemia  (continued).
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Highly immature, polymorphic blasts. The nucleus is
eccentric with dispersed, reticulated chromatin and
1-3 prominent nucleoli. The cytoplasm is non-granular,
basophilic, and very similar in appearance to platelets,
with pseudopods or granulations. Micromegakaryocytes
and fragments of megakarioblasts are seen in peripheral
blood (giant platelets, some highly degranulated).
Immunophenotype
•CD41 + 
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M5a acute monoblastic leukaemia:
Large blasts with rounded nucleus and dispersed, 
immature chromatin (1-3 nucleoli) and mod rately large
and intensely basophilic yt pl sm. The cytoplasm may 
show ome Auer rods and/or prolongati ns 
and granulations.
M5b acute monocytic leukaemia
Promonocytes hav  a rounded or kidney-shaped
nucleus with  l ss basophilic cytopla m that is
more highly granulated than monoblasts and contains
some vacuoles. A findings of erythrophagocytosis
together with monocytic blasts suggests a t(8;16)
translocation.
M6a erythroid leukaemia with proliferation of mixed blasts:
Over 50% erythroid precursors and around 30% myeloblasts.
Morphology of erythrocytes in peripheral blood is greatly changed, 
with schistocytes, “pincered” or mushroom-shaped cells, 
and spiculated echinocyte and acanthocyte cells.
M6b pure erythroid leukaemia:
Erythroids make up 80% of bone marrow
cells, with less than 3% myeloid cells.
Erythrocytes in peripheral blood consist
of macrocytes, basophilic stippling,
Howell-Jolly bodies or Cabot rings.
 Morphology:
Large blasts, moderate nucleo:cytoplasm
(n:c) ratio and variable basophilia. The
nucleus may be rounded, kidney-shaped 
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Figure  4  French-American-British  (FAB)  classificati n  of  acute  myeloblastic  leukaemia  (continued).
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Highly immature, polymorphic blasts. The nucleus is
eccentric with dispersed, reticulated chromatin and
1-3 prominent nucleoli. The cytoplasm is non-granular,
bas philic, a d v ry similar in appeara ce to platelets,
with pseudopo s or granul tions. Micromegakaryocytes
and fragments f megak ri blast  are seen in peripheral
blood (giant platelets, some highly degranulat d).
Immunophenotype
•CD41 + 
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M5a acute monoblastic leukaemia:
L rge blasts with rounded nucleus and dispersed, 
immature chromati  (1-3 nucleoli) an  moderately large
and intensely basophilic cytoplasm. The cytop asm may 
show some Auer rods and/or prol ngations 
and granulations.
M5b acute monocytic leukaemia
Promonocytes have a rounded or kidney-shaped
nucleus with a less basophilic cytoplasm that is
more hig ly granul ted than m noblasts nd contains
some vacuoles. A findings of erythroph gocytosis
together with mo ocytic blasts suggests a (8;16)
translocation.
M6a erythroid leukaemia with proliferation of mixed blasts:
Ov  50% erythroid precurso s and around 30% myeloblasts.
Morpholog  of erythrocytes in peripheral blood is greatly changed, 
wit  schist cytes, “pincered” or mushroom-shaped cells, 
and spiculat d echinocyte and acanthocyte cells.
M6b p re rythroid leukaemi :
Erythroids make up 80% of bone marrow
cells, with less than 3% myeloid cells.
Erythrocyte  in peripheral blood consist
of macrocytes, basophilic stippling,
Howell-Jolly odies or Cabot rings.
 Morphology:
Large blasts, moderate nucleo:cytoplasm
(n:c) r tio and va iable bas philia. The
nucleus may be rounded, kidney-shaped 
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Figure  4  French-American-British  (FAB)  classification  of  acute  myeloblastic  leukaemia  (continued).
r l  f l i  
 l ifi ti  f t  l l ti  l i
r l :
i ly i t r , ly r ic l sts.  cl s is
cc tric it  is rs , r tic l t  c r ti  
-  r t cl li.  cy l s  is - r l r,
s ilic,  v ry si il r i  r c  t  l t l ts,
it  s ds r r lati s. icr k ry cyt s
 fr t  f k ri l sts r  s  i  ri r l
l  ( i t l t l ts, s  i ly r l t ).
I t
•   
•     
•   
•  
•   
•  
t  r t r i
l i
t  r ti
l i
I t
•   
•     
•    
• lyc ri   
• lyc ri   
 t  l ti
l i  
 t  ti
l i  
 c t  l stic l k i :
r  l sts it  r  cl s  is rs , 
i t r  c r ti  ( -  cl li)  r t ly l r
 i t s ly s ilic cyt l s .  cyt l s  y 
s  s  r r s / r r l ti s 
 r l ti s.
 c t  cytic l k i
r cyt s v   r  r ki y-s
cl s it   l s  s ilic cyt l s  t t is
r  i ly r l t  t  l st   c t i s
s  v c l s.  fi i s f ryt r cyt si
t t r it  cytic l sts s st   ( ; )
tr sl c ti .
 ryt r i  l k i  it  r lif r ti  f ix  l sts:
v   ryt r i  r c rs s  r   y l l sts.
r l  f ryt r cyt s i  ri r l l  is r tly c , 
it  sc ist cyt s, “ i c r ” r s r -s  c lls, 
 s ic l t  c i cyt  c t cyt  c lls.
 r  ryt r i  l k i :
ryt i s k    f  rr
c lls, it  l ss t   y l i  c lls.
ryt r cyt  i  ri r l l  c sist
f cr cyt s, s ilic sti li ,
ll-J lly i s r t ri s.
 r l :
r  l sts, r t  cl :cyt l s
( :c) r ti   v ri l  s ili . 
cl s y  r , ki y-s  
r irr l r. cl li r  s lly r i t.
I t
•  








•   
•    
•    
• c 
• -  
•  
i   r - ri - ritis  ( )  l ssi ti  f  t  l l sti  l i  ( ti ).
    
l i i i l l i l i
l l i l i
i i i l i i i
l l i l i
i i
l l i l i
i i
l ti  l i  
I t
•   






 r l  -  l t . i - i
l t , r  l , fi  r ti ,
ili  - r l r t l ,
r i t l li.
l :
i - i  l t  it  i  l : t l  ( : )
r ti , r  l i it  i t r , i r  r ti
it   r r  r i t l li. l t   
fi  r ili  r l ti  r i l t  r r  i
t  t l  i   t   f 
l :
ll t  i - i  l t  it  i  l :
t l  ( : ) r ti   r  l i ti
l t  i   r r f t  t l .  l
 i r , i t r  r ti  it   r r
l li.  t l  i  ili    t i
tr  f ri r  r ili  r l ti  r i l t  
r r .
l :
t, i t l  r ili  r l ti .
 l  i  ll  ti  i  r
(r if r )  i  it r irr l r r il  it  
 l ft. r l  ili  t l   t  t
r lif r ti  f r ili  r l ti .  t i l
r l t  l  t i  l t  r li t r-
 r t lli  t l i  i l i  ifi  t
t i  t  f l i .  ll  f r  l ,
t iff r fr  r r  i  t t t    t l r
tr t r   l tr i  i r .
I t
•   
•   







• -  /-




•   
•   
•
••  /-
t  rt  f: t  l i  l i  t i l , 
i   i i i   l i i    l l i  l i   l i i    l l i
l i
     
         
      
     
, ,
   
     
        
        
110  .  Ladines-Castro  et  al.
 classification of acute yeloblastic leukae ia
c t  y l l stic l k i
it  i i l iff r ti ti
t  t  
t  t r t  
Pro yelocytic leukae ia 
I t
•   






 r l  -  l t . i - i
l t , r  l , fi  r ti ,
ili  - r l r t l ,
r i t l li.
r
all o ediu sized blas s i h high nucleo
cy oplas n c a io and ounded nuclei so e i es
located in a co ne  of the cytoplas . The nucleus
sho s dispersed, i ature chro atin ith one or ore
nucleoli. The cytoplas  is basophilic and can contain
traces of pri ary azurophilic granulation or isolated 
Auer rods.
Morphology:
Abundant, intensely azurophilic granulation.
The nucleus is usually monocytic in appearance
(reniform) and is either irregular or bilobed with a
deep cleft. Scarcely basophilic cytoplasm due to the
proliferation of azurophilic granulation. Some atypical
promyelocytes also contain elongated or splinter-
shaped crystalline cytoplasmic inclusions specific to
this type of leukaemia.These usually form clumps,
but differ from Auer rods in that they show a tubular












l i l i i l
3
Figure  3  French-American-British  (FAB)  classification  of  acute  myeloblastic  leukaemia.  FAB  classification  of  acute  myeloblastic
leukaemia.
FAB  classification  of  acute  myeloblastic  leukaemia
Figs.  3 and  4 show  the immunophenotype  and  morphology  of
acute  myeloblastic  leukaemias  (AML),  together  with  micro-
scope  images  and  a brief  summary.9,11,12
M0 Acute  myeloblastic  leukaemia
Myeloblastic  leukaemia  with  minimal  differentiation,  or
M0-AML,  is  particularly  difficult  to  diagnose  from  the mor-
phological  point of  view  because  the  blasts  present  both
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Highly immature, polymorphic blasts. The nucleus is
eccentric with dispersed, reticulated chromatin and
1-3 prominent nucleoli. The cytoplasm is non-granular,
basophilic, and very similar in appearance to platelets,
with pseudopods or granulations. Micromegakaryocytes
and fragments of megakarioblasts are seen in peripheral
blood (giant platelets, some highly degranulated).
Immunophenotype
•CD41 + 
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 Acute mo ocytic
leukaemia 
M5a acute monoblastic leukaemia:
Large blasts with rounded nucleus and dispersed, 
immature chromatin (1-3 nucleoli) and moderately large
and intensely basophilic cytoplasm. The cytoplasm may 
show some Auer rods and/or prolongations 
and granulations.
M5b acute monocytic leukaemia
Promonocytes have a rounded or kidney-shaped
nucleus with a less basophilic cytoplasm that is
more highly granulated than monoblasts and contains
some vacuoles. A findings of erythrophagocytosis
together with monocytic blasts suggests a t(8;16)
translocation.
M6a erythroid leukaemia with proliferation of mixed blasts:
Over 50% erythroid precursors and around 30% myeloblasts.
Morphology of erythrocytes in peripheral blood is greatly changed, 
with schistocytes, “pincered” or mushroom-shaped cells, 
and spicul ed echinocyte and acanthocyte cells.
M6b pure erythr id leukaemia:
Erythroids make up 80% of bone marrow
cells, with less than 3% myeloid cells.
Erythrocytes in peripheral blood consist
of macrocytes, basophilic stippling,
Howell-Jolly bodies or Cabot rings.
 Morphology:
Large blasts, moderate nucleo:cytoplasm
(n:c) ratio and variable basophilia. The
nucleus may be rounded, kidney-shaped 
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Figure  4  French-American-British  (FAB)  classification  of  acute  myeloblastic  leukaemia  (continued).
 
Figure 1 - FAB classification of AML (adapted from 40). 
 
 
Therefore, in 2001 the WHO introduced a new classification system that was further 
improved in 2008 27. The last revision of 2016 takes also into account the genetic 
landscape in addition to morphology, immunophenotype and clinical presentation, thus 
defining six major groups: AML with recurrent genetic abnormalities; AML with 
myelodysplasia-related features; therapy- related AML; AML not otherwise specified; 
myeloid sarcoma; and myeloid proliferation related to Down syndrome28. Moreover, 
further 11 subtypes were identified among those patients characterized by recurrent genetic 
abnormalities based on the peculiar chromosomal translocations. AML carrying NPM1 and 
CEBPA mutations were introduced as part of the 2008 revision. Nonetheless, only in 2016 
revision AML with BCR-ABL1 translocation and RUNX1 mutated AML were considered 












Figure 2 - Classification system approved in 2016 37. 
 
The relevance of genetic alterations was recognized also for the prognosis of AML 
patients, thus strongly influencing the complete remission (CR) and patients’ overall 
survival (OS). Accordingly, AML were stratified into favorable, intermediate or adverse 
prognostic risk groups based on their mutational profile alone. In this context, t(8;21), 
t(15;17) or inv(16) chromosomal alterations grant a favorable prognosis, while three or 
more chromosomal abnormalities in the absence of any of the recurrent genetic 
abnormalities (complex  karyotype) have all been associated with a significantly poor 
prognosis. Cytogenetically normal AML (CN-AML) representing the group of patients 
without any recognizable translocation or cytogenetic alteration, have been reported to 
display an intermediate risk with a 5-year survival rates between 35% and 45% 41  (Figure 
3). 
 
Figure 3 - Risk assessment in patients with acute myeloid leukemia 42. 
Voso et al. Advanced Technologies for MRD Assessment in AML
FIGURE 1 | ELN-2017 risk stratification of AML by genetic abnormalities [Adapted from Dohner et al. (6)].
this context, NPM1-mutated AML with FLT3-ITD AR < 0.5
(FLT3-ITDlow) are classified s prognostically favorable, similar
to NPM1-mutated/FLT3 wild-type AML (6). Notably, this is
the first time that FLT3-ITD mutated AML are classified
as “favorable” (9). By contrast, NPM1 wild-type AML with
FLT3-ITD AR >0.5 (FLT3-ITDhigh) are classified as “adverse-
risk,” while AML NPM1-mutated/FLT3-ITDhigh are considered
“intermediate-risk” (6) (Figure 1).
Prognostic assessment of AML at diagnosis has strong clinical
relevance, allowing for instance to allocate patients with high-
risk disease to receive allogeneic stem cell transplantation (allo-
SCT) in first remission as part of frontline therapy (10, 11), while
patients with favorable-risk AMLwould not be candidates to allo-
SCT (6). Conversely, the indication for allo-SCT in first complete
remission for the large subset of patients with intermediate-risk
disease is currently a matter of debate (12). These figures may
further change in the near future due to the incorporation of
targeted treatments added to conventional chemotherapy, as the
recently approved FLT3 inhibitors midostaurin or quizartinib
(13, 14), which may change risk-stratification according to FLT3
mutation status.
Recent technological advances have contributed to increase
the list of AML mutations associated to adverse prognosis. In
particular, in the past decade, the advent of Next Generation
Sequencing (NGS) technologies led to the identification of
novel molecular abnormalities that shed new light into the
pathogenesis and prognosis of the disease, and have been
therefore, incorporated in the revised ELN guidelines (6, 15, 16).
Despite improved genetic classification and CR rates close
o ∼80%, more than 50% of adult patients with AML will
undergo disease relapse after initial treatment (12, 17), due to
the emergence of resistant clones surviving therapy (18). In fact,
although an accurate quantification of blasts may be provided by
optical microscopy when declaring morphological CR (mCR), a
relevant amount of residual leukemic cells, estimated to range
from 1010 to 1012 may still persist in a normal adult (19). A
precise estimate of residual disease below the threshold of mCR
represents a critical issue in prognostic assessment and in the
post-remission decision-making process in AML. This is the
purpose of techniques aiming at minimal residual disease (MRD)
detection (20). However, since the capability to detect leukemic
cells depends on the methodology used, the term “measurable”
residual disease has been recently proposed to indicate the levels
of leukemic cells detectable by modern technologies, which
are characterized by very high sensitivity (19). The advantage
of identifying by molecular methods MRD levels predictive
of clinical relapse has been proven for acute promyelocytic
leukemia (APL), where a positive PML-RARA test after the end
of consolidation therapy is invariably associated to overt relapse
(21). As a consequence, pre-emptive treatment of molecular
relapse is currently recommended as standard practice in APL
and is being now considered in some specific non-APL AML
subsets (22).
In this context, the updated ELN recommendations
introduced the concept of MRD-negative mCR as a new
outcome definition (6), in cases where a given genetic or
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associated with t(8;21) or inv(16), and its presence carries significant
implications regarding prognosis. Similarly, NMP1 (a class II mutation)
frequently occurs in conjunction with the class I mutation FLT3-ITD,
or mutations in the epigenetic genes DNMT3A and IDH-1 or IDH-2.6
Most of the clinical manifestations of AML reflect the accumulation
of malignant, poorly differentiated myeloid cells within the bone
marrow, peripheral blood and infrequently in other organs. The
majority of patients presents with a combination of leuko-
cytosis and signs of bone marrow failure such as anemia and
thrombocytopenia. Fatigue, anorexia and weight loss are common
complaints; lymphadenopathy and organomegaly are not typically
seen. If left untreated, death usually ensues within months
of diagnosis secondary to infection or bleeding. The diagnosis
of acute leukemia is established by the presence of 20% or more
blasts in the bone marrow or peripheral blood.17 AML is further
diagnosed by demonstrating the myeloid origin of these cells
through testing for myeloperoxidase activity, immunophenotyp-
ing or documenting the presence of Auer rods. The latter finding
consists of azurophilic, often needle-shaped cytoplasmic inclusion
bodies that are commonly seen in APL, acute myelomonocytic
leukemia and the majority of AML with t(8;21). The diagnosis of
AML can also be established in the presence of an extramedullary
tissue infiltrate, or a documented t(8;21), inv(16) or t(15;17) in the
appropriate clinical setting, regardless of the blast percentage.18
CLASSIFICATION
The French–American–British classification system represents
the first attempt to distinguish between different types of AML.
Established in 1976, it defines eight subtypes (M0 through M7)
based on the morphological and cyto-chemical characteristics
of the leukemic cells. In 2001, as part of an effort to integrate
advances made in the diagnosis and management of AML, the
World Health Organization (WHO) introduced a new classification
system followed by a revised version in 2008.18 Later in 2016
a new revised version was released, the WHO classification of AML
distinguishes itself by incorporating genetic information with
morphology, immunophenotype and clinical presentation to
define six major disease entities: AML with recurrent genetic
abnormalities; AML with myelodysplasia-related features; therapy-
related AML; AML not otherwise specified; myeloid sarcoma; and
myeloid proliferation related to Down syndrome (Table 1).19
Among cases of AML with recurrent genetic abnormalities, 11
subtypes are further delineated according to distinct chromoso-
mal translocations. In addition, the provisional entities AML with
mutated NPM1 and AML with mutated CEBPA were introduced
as part of the 2008 revision,18 while AML with BCR-ABL1 and
AML with mutated RUNX1 were introduced as part of the 2016
revision.19 Genetic abnormalities also inform the diagnosis of AML
with myelodysplasia-related changes: along with a history of MDS
or morphological evidence of dysplasia in two or more myeloid
cell lineages, the presence of myelodysplasia-related cytogenetic
abnormalities such as monosomy 5 or 7, and deletion 5q or 7q
identify cases of AML with myelodysplasia-related features.
PROGNOSTIC FACTORS
Accurate assessment of prognosis is central to the management
of AML. By stratifying patients according to their risk of treatment
resistance or treatment-related mortality (TRM), prognostic factors
help guide the physician in deciding between standard or
increased treatment intensity, consolidation chemotherapy or
allogenic hematopoietic stem cell transplant, or more fundamen-
tally in choosing between established or investigational therapies.
Among clinical factors, increased age and poor performance
status are both associated with lower rates of complete remission
(CR) and decreased overall survival (OS).3,20 Age and performance
status at diagnosis similarly help to predict the risk of TRM,
although multivariate model analyses suggest that other variables
such as platelet count, serum creatinine or albumin rather than
age itself account for most of the increased risk of TRM seen
in older patients.21 Therapy-related AML and AML associated with
a prior hematological malignancy also carry a significantly poorer
prognosis.22 Although clinical factors have an important role in
Table 1. WHO classification of AML and related neoplasms
Types Genetic abnormalites
AML with recurrent genetic abnormalities AML with t(8:21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
APL with PML-RARA
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A
ML with t(6;9)(p23;q34.1); DEK-NUP214
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1
AML with BCR-ABL1 (provisional entity)
AML with mutated NPM1
AML with biallelic mutations of CEBPA
AML with mutated RUNX1 (provisional entity)
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms









Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down syndrome Transient abnormal myelopoiesis
ML associated with Down syndrome
Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ML, myeloid leukemia; WHO, World Health Organization.
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1.3.2 Standard therapy 
 
During the last decade, significant improvements in the treatment of AML have been 
obtained with the introduction of target agents. However, the standard therapy is still 
represented by chemotherapy that is conventionally administered to patients into two 
different phases, the so term “induction” and the further “consolidation” 37.  
During the first phase, patients undergo to a short but intensive period of treatment aimed 
at reducing the number of blasts within the BM, while the consolidation phase is 
administered to eliminate the any remaining leukemia cells. In the second phase, 
chemotherapy is given in cycles, with each period of treatment followed by a rest period 
allowing patients’ recovery 37. The mainstay of induction therapy in younger patients 
(called “7 + 3 regimen”) consists in the administration of Cytarabine (cytosine arabinoside 
or ara-C) for 7 days along with an anthracycline (replaced by fludarabine or etoposide in 
cardiopathic patients) for 3 days 43. For some particular subtype of AML, a third drug 
could be added to implement the treatment. For instance, in the case of CN-AML carrying 
the FLT3 mutation, the multi-kinase inhibitor midostaurin might be given along with 
chemotherapy. For some patients having a CD33-positive AML, the gemtuzumab 
ozogamicin, a humanized IgG4 anti-CD33 could represent a combined approach 43. 
Following the first cycle of chemotherapy, a second round could be given whether in the 
BM are detected leukemic cells. Importantly, the induction phase usually does not induce 
the complete elimination of blast in patients, but patients achieve the remission, meaning 
that within the BM, fewer than 5% blast cells are observed, upon chemotherapy treatment. 
Further treatments in the consolidation phase are administered depending on patients’ 
status. In younger patients from 3 to 4 cycles with high-dose cytarabine (HiDAC) are 
usually employed 44. This treatment might be followed by an allogeneic stem cell 
transplant or an autologous stem cell transplant. Older patients or patients who developed 
severe side effects during the induction treatment receive low-intensity chemotherapy with 
a single agent or a combination of drugs (chemotherapy and target drugs) or a non-
myeloablative stem cell transplant 45. It has been reported that after the induction therapy 
60%-80% of younger and 40%-60% of older patients can reach a CR 46,47. However, 
despite the intensive consolidation therapy approximately half of younger and 80%-90% of 




1.3. 3 Novel drugs 
 
Besides to conventional therapies, recently, some novel drugs have been approved given 
the increase understanding in AML molecular underpinnings 48. These agents include 
FLT3-ITD inhibitors, such as sorafenib, quizartinib and midostaurin, signal transducer and 
activator of transcription (STAT) inhibitors, i.e. STAT-3 inhibitors C188-9 and MM-206 
and the antipsychotics pimozide, and IDH1/IDH2 small molecule inhibitors, including 
BAY-1436032, Enasidenib (AG-221) and the Ivosidenib (AG-120).  
 
 
1.4 The BM microenvironment in normal hematopoiesis  
 
As previously discussed in 1.1-chapter, haematopoiesis is a complex process that is finely 
tuned by cell-intrinsic mechanisms, but also, and to large extent by cell-extrinsic signals 
provided by the BM microenvironment, also termed “BM niches”. The concept of BM 
niches, described as an anatomical and functional unit of physiology that integrates 
endocrine, autocrine, and paracrine signaling sustaining HSC was introduced for the first 
time by Schofield in the 1978 49. In this context, he pointed out the close link and the 
dependence between the microenvironment and the fate of HSCs 49. Indeed, he stated that 
HSC self- renewing, differentiation, mobilization, quiescence and proliferation are deeply 
influenced by the surrounding cells constituting the BM microenvironment 49. During the 
last decades, most of the cellular components of the BM niche have been identified 
including mesenchymal stem cells, osteoblasts, endothelial cells, adipocytes, sympathetic 
nervous system, megakaryocytes, and macrophages 50,51 (Figure 4). Within the BM, two 
major niches are described and are represented by the “endosteal niche” and the “vascular 
(also termed “central”) niche”, which are strictly anatomically and functionally 











Figure 4 - Schematic representation of the key cell types and functional features of 
the haematopoietic stem cell niches 52. 
 
 
1.4.1 Osteoblastic niche (endosteal niche) 
 
The endosteal niche is found closer to the bone surface and it is involved in HSC 
quiescence maintenance. This niche is mainly formed by osteoblasts, osteoblastic 
progenitors, and osteoclasts lining. The endosteal surface of the bone in nearly closed to 
the vessels 53,54. One of the first demonstration of the relevance of osteoblasts in supporting 
HSC growth was obtained by Taichman, that using in vitro approaches exploiting human 
osteoblasts and human hematopoietic progenitor cells highlighted the importance of 
cytokines produced by endosteal niche in hematopoiesis regulation 55,56. In addition, it has 
been shown that in transgenic mice characterized by the constitutive activation of the 
parathyroid hormone receptor, the increase of osteoblasts producing high levels of the 
Notch ligand jagged 1 was associated with a parallel enhancement of HSC frequency in the 
BM 57. In line with these findings, the conditional ablation of Col2.3-labeled osteoblast 
lineage in mice leaded to a reversible BM hypocellularity with a decreased HSC number 
accompanied with an increased extramedullary hematopoiesis 58. Accordingly, Bowers et 
al demonstrated that osteoblast ablation resulted in the increase of the LSK Flt3-
CD150+CD48- long-term HSC (LTHSC) phenotype and with the decrease of LSK Flt3-
CD34-CD49b-CD229- LTHSC subpopulation59. Moreover, osteoblasts depleted mice were 
characterized by the loss of quiescence and reduced long-term engraftment and self-
renewal ability 59. Moreover, the depletion of Osterix+ cells thus inhibiting osteolineage 
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differentiation resulted in the loss of hematopoiesis in the BM of adult mice 60. Several 
molecules released by osteoblasts are able to influence HSC fate. Stier et al demonstrated 
that among all, osteopontin (OPN) deletion in mice induced an increase of HSC number in 
the BM, showing that OPN can be considered a negative regulator of HSCs 61. Another 
important factor expressed by differentiated osteoblasts is represented by agrin, a 
proteoglycan involved in the neuromuscular junction. Indeed, apoptosis of CD34+CD135- 
Lin−Sca-1+c-Kit+ (LSK) cells and impaired hematopoiesis was observed in agrin-
deficient mice, conditions that were reverted by an agrin-sufficient stroma 62.  
Regarding osteoclasts, Mansour et al demonstrated that the impaired osteoclast activity 
resulted in a reduced osteoblastic differentiation that in turn leaded to the compromised 
HSC homing to the BM 63. It has also been reported that the use of bisphosphonates, a 
group of drugs that inhibit bone resorption mediated by osteoclasts reduced the frequency 
of primitive HSCs, while supporting the expansion of the hematopoietic progenitors 64.  
Although all these evidence, the real contribution of osteogeniclineage cells has been 
questioned 65. Recent studies performed in mouse models, including 3D imaging studies 
66,67 have shown that HSCs are not significantly associated with osteoblasts. Moreover, it 
has been reported that the specific deletion of CXCL12 68,69 or stem cell factor (SCF) 70 
from osteoblasts didn’t influence HSC proliferation or their frequency. In this line, 
hepatocytes and not osteoblasts, has been reported as the major functional source of 
thrombopoietin (THPO) required for HSC maintenance in mice 71. Given this evidence, 
even if osteoblasts were one of the first cell population that was reported to be involved in 
HSC regulation, nowadays the most supported hypothesis is that osteolineage cells sustain 
the maintenance of more committed haematopoietic progenitors, in particular, the 
lymphoid lineage 72.  
 
1.4.2 Vascular niche (central niche) 
 
Vascular niche is found closer to the central zone of the BM and is mainly formed by 
endothelial cells (ECs), which line the lumen of blood vessels. It has been reported that 
periarteriolar vascular niche as far as sinusoids strongly regulate the proliferation and 
differentiation of HSCs. Small arterioles seem to be more resistant to damages compared 
to sinusoids, suggesting that periarteriolar vessels might play an important role in 
haematopoiesis recovery after irradiation. Moreover, arterioles are characterized by a 
population of pericytes expressing neural/glial antigen 2 (NG2), that are involved in HSC 
quiescence maintenance. The depletion of NG2+ cells resulted in the reduction of HSCs 
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with long-term repopulating ability and expansion of cycling HSCs 67. Moreover, 
pharmacological, or genetic activation of HSC proliferation affect their distribution with 
cycling HSCs that moved from NG2+ peri-arteriolar niches to leptin receptor positive 
(LepR+) peri-sinusoidal niches in mice 67. In this context, deletion of CXCL12 67 or SCF 73 
from NG2+ pericytes leaded to the mobilization of quiescent HSCs to the circulation, and 
therefore results in a reduction of HSC numbers in the BM of transgenic mice. Hooper et 
al. demonstrated that the conditional deletion of vascular endothelial growth factor 
receptor 2 (Vegfr2) in adult mice impairs sinusoidal regeneration and HSC reconstitution 
after myelosuppression 74.   
In vitro studies demonstrated that ECs could induce HSC expansion through Notch ligands 
75 and Akt-mTOR-activated endothelial cells regulates HSC self-renewal by releasing 
CXCL12 and SCF 76. Similarly, EC-specific deletion of Notch ligand, Jagged-1, decreased 
HSC frequency and inhibited hematopoietic regeneration after irradiation 77. Furthermore, 
EC-specific inhibition of NF-κB induced HSC self-renewal and reduced the radiotherapy-
related damage to the hematopoietic system 78. Other EC-related important factors that 
support BM hematopoiesis are represented by specific surface markers, including E-
selectins, P-selectin, vascular cell adhesion molecule 1 (VCAM-1) and intercellular 
adhesion molecule (ICAM) 1 as demonstrated using in vivo approaches and selective 
knockout mice 79. 
 
1.4.3 Mesenchymal Stem Cells (MSCs) 
 
Mesenchymal stem cells (MSCs) are rare elements within the BM, counting the 0.01% of 
total BM cells 80. They were firstly described in 1867 as non-hematopoietic cells within the 
BM displaying self-renewal abilities 49. It is only in the 1970 that Dr. Friedenstein reported 
the isolation of plastic-adherent stromal cells that were able to form fibroblastic-like 
colonies and can differentiate into osteoblasts and reconstitute the hematopoietic niche in 
vivo after subcutaneous transplantation 81,82. Nowadays, the International Society of 
Cellular Therapy (ISCT) recognizes MSCs on the basis of their capacity of adhesion to 
plastic; their ability to differentiate into other cell types, such osteoblasts, adipocytes or 
chondrocytes and their specific phenotype 83.  Mouse MSCs (mMSCs) were described as 
CD45−Ter119−PDGFRα+Sca-1+/- cells 84. Moreover, they were found to secrete CXCL12, a 
crucial factor that regulates HSC homeostasis 84. Regarding humans, the minimum criteria 
to define human MSCs (hMSCs) are the expression of CD105, CD73, and CD90, and the 
lack of CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR expression. Other 
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surface antigens commonly expressed by hMSCs include CD13, CD29, CD44, and CD10 
85.  
Even if generally recognized as MSCs, more recently, different studies have demonstrated 
the heterogeneity of MSCs, identifying different sub-population (i.e. LepR+) cells, 
CXCL12-abundant reticular cells (CAR) cells, nestin+ cells and CD146+ cells) able to 
differentially regulate HSC biology and characterized by the expression of peculiar 
markers 49. In particular, in humans, CD146+ cells are usually found in the vascular niche 
and are characterized by the expression of Angiogenin-1 (Ang-1) and CXCL12 that allow 
their interaction with Tie-2+ and CXCR4+ HSC and endothelial cells 86. Nestin+ (Nes+) 
cells are mostly perivascular and support the homing and reduces the mobility of HSCs 49. 
They regulate the quiescence of HSCs through the release of several factors, such 
CXCL12, SCF, Ang-1, IL-7, VCAM-1 and OPN 86. CAR cells are mainly found in the 
endosteal region of the BM and are characterize by the high expression of CXCL12, in 
turn regulating HSC cell cycle and self-renewing and promoting HSC quiescence 87. They 
are also a source of SCF and IL-7 that is crucial for the lymphoid progenitor and mature B 
cell maintenance 88,89 .  
As reviewed by Pinho and Frenette 72, the use of transgenic mouse models suggested that 
Nes–GFP+ cells overlap substantially with LepR+ cells in the BM. In detail, whole-mount 
3D imaging of the BM has shown that LepR+ cells overlap with Nes-GFPlow cells and CAR 
cells that are scattered near sinusoids while Nes–GFPhigh cells expressing the pericyte 
marker NG2 67or the smooth-muscle marker MYH1173  are associated with arterioles 
(Figure 4).  
 
1.5 The BM microenvironment in myeloid malignancies  
 
Increasing evidence demonstrated that BM microenvironment contributes to leukaemia 
development and progression and several works suggested that it is also influenced by 
leukemic cells 90. Advances in BM imaging technologies clearly showed that various cell 
types are involved in leukemogenesis, including osteoblasts, perivascular stromal cells, 







1.5.1 Crosstalk between leukemic cells and BM niche  
BM cell and blast interactions play a crucial role in the development of AML and can 
mediate the onset of resistance to therapy. In this context, niche stromal cells have been 
reported to prevent cytarabine-induced apoptosis. This phenomenon seemed to be 
associated with the release of soluble factors that stimulated the up-regulation of BCL-2 in 
human leukemia cells and occurred only when blasts were co-cultured with stromal cells 
91. Moreover, the expression of the integrin α4β1 and its binding to the VCAM1 or 
fibronectin induced chemoresistance of AML cells 92. Regarding leukemia development, 
several are the BM cells/blasts-mediated mechanisms that have been demonstrated. The 
CXCR4/CXCL12 axis has been reported as a major regulator of the crosstalk between 
leukemia cells and BM microenvironment. Generally, this signalling is involved in the 
retention of blasts in the BM, thus, higher expression of CXCR4 on AML cells has been 
considered as a negative prognostic factor93.  The expression of CD44, a protein involved 
in cell–cell and cell–matrix interactions, on AML cells was shown to favour blast homing, 
motility and invasive properties 93-95 and its higher expression along with mmp9 
overexpression is associated with aggressiveness and relapse 96. In vivo studies performed 
by Miller et al showed that integrin β3 was crucial for MLL-AF9 AML development while 
it was dispensable for normal hematopoietic stem and progenitor cells engraftment 92. In 
addition, glycoprotein CD98 expressed on AML cells have been reported to bind the β1 
and β3 integrins on BM niche cells. This interaction promoted murine as far as human cells 
spreading, migration, survival, and growth 97. Nishioka et al demonstrated that CD82 
mediates adhesion of human AML leukemic stem/progenitor cells to the extracellular 
matrix, supporting the engraftment and the progression of the disease and speculated that 
this signalling might provide an advantage over normal hematopoietic stem and progenitor 
cell (HSPCs) 98-100. Moreover, Moschoi et al by using co-colture and in vivo experiments 
observed that stromal cells were able to transfer functional mitochondria to AML cells 
influencing their survival and resistance to chemotherapy 101.  Accordingly, Marlein et al 
showed that the inhibition of mitochondrial transfer enhanced AML cell death and 
prolonged survival of mice transplanted with patient-derived AML cells 101.  
Moreover, Von der Heide et demonstrated that BM-MSC derived from AML patients 
display transcriptional and epigenetic alterations that involved proteoglycans, adhesion 
molecules, endocytosis pathways, cytokine–cytokine receptor interactions, chemokine 
signaling and the impairment of crucial metabolic pathways 102.  Increasing evidence have 
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shown a crucial role of exosomes released by AML cells that can mold the 
microenviroment supporting AML survival and development. In particular, it has been 
shown that AML-derived exosomes enhanced AML growth in vivo, while the inhibition of 
their secretion through the targeting of Rab27a results in a significantly delay of leukemia 
development. Indeed, AML exosomes are able on one hand to induce the expression of the 
Dickkopf-related protein 1, a protein involved in the osteogenesis and on the other, 
downregulate CXCL12, KITL and insulin growth factor (IGF) 1 that represent important 
factors supporting normal hematopoiesis 103.  
 
1.5.2 BM stromal cells contribution to AML development 
Different studies during the last decades have clearly shown that MSCs are able to affect 
leukemia growth in vitro and in vivo (Figure 5) 104.  
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Table 1. Studies reporting that MSCs affect hematologic malignancy by inhibiting/promoting tumor growth.





B-Acute lymphoblastic leukemia 
(patient cells)
Prevent of leukemic cells apoptosis Prevention of apoptosis by 






AML (patient cells) Improvement of leukemic cell 
survival 
Inhibition of drug-induced 






Chronic myeloid leukemia (K562 
and BV173 cell lines) and acute 
myeloid leukemia (KG1a cell 
line)
Induce leukemic cell growth via 
reducing apoptosis
Formation of a leukemic stem cell 
niche to preserve the 
self-renewal ability of cancer 
cells




al cell line 
Acute myeloid leukemia (U937, 
HL-60, and HL-60/VCR cell lines)
Induction of specific gene 
expression, leading to cell cycle 
arrest
Induction of apoptosis via 
modulation of Bcl-2 and active 
Caspase-3




Acute myeloid leukemia (HL-60 
cell line) and chronic myeloid 
leukemia (K562 cell line)
Inhibit cancer cell proliferation Induction of cell cycle arrest 
through cytokine secretion such 
as DKK1





Chronic myeloid leukemia 
(K562 cell line)
Inhibit leukemic cell growth and 
apoptosis
Induction of apoptosis via 
phosphorylation of the Akt and 
bad proteins 





Acute myeloid leukemia (HL-60 
cell line) and chronic myeloid 
leukemia (K562 cell line)
Inhibit leukemic cell growth Potent proliferation inhibition of 
leukemic cells via activation of 





Lymphoma (BJAB and SKW6.4 
cell lines)
Inhibit lymphoma cell growth Modulation of the lymphomas 
stromal network by inducing an 
increase of intra-tumor necrosis







Chronic myeloid leukemia 
(K562 and patient cells)
Increase anti-apoptotic ability of 
cancer cells
Regulation of apoptosis-related 
protein expression and 
activation of the Wnt signaling 
pathway





T-Acute lymphoblastic leukemia 
(Jurkat cell line)
Inhibit Jurkat cell proliferation Potential shielding effect of MSCs 






Acute lymphoblastic leukemia 
(patient cells)
Protect of leukemic cells from 
apoptotic cell death
Inhibition of tumor suppressive 
activity by PGE2 secretion and 
activation of cAMP-PKA signaling 
pathway




B-lymphoma (A20 cell line) Inhibit leukemia/lymphoma cell 
growth
Cell cycle arresting of lymphoma 
cells due to reduction of 
interleukin (IL)-10 secretion 




Acute lymphoblastic leukemia 
(Reh, CCRF-CEM, SUP-T1, and 
CCRF-HSB2 cell lines)
Induce leukemia cell growth Induction of cancer cell growth by 
increasing the luciferase activity




Chronic myeloid leukemia 
(K562 cell line)
Promote apoptosis and change 
cell cycle distribution of leukemic 
cells
Induction of apoptosis by 
secreting the TIMP-1 and 
CINC-1 cytokines and via BAX 
and caspase-3 cascade pathways
terms stroma and MSCs to the scientific community and 
indicated that MSCs are able to differentiate into the adipo-
cyte cell lineage [3]. MSCs, as well as other types of adult 
stem cells, are characterized by self-renewal capability, clo-
nogenic efficiency, and multi-lineage differentiation 
capacity. In general, MSCs are isolated by their capacity 
to adhere to culture-dish plastic surfaces. Cells can be ex-
panded in culture plates and immunologically characterized 
by a specific panel of markers. Because of the lack of unique 
and definitive cellular markers, the characterization of MSCs 
remains difficult. For this reason, the International Society 
for Cellular Therapy suggested three minimal criteria for 
the characterization of MSCs: (a) plastic adherence, (b) ex-
pression of markers related to mesenchymal cells such as 
CD73, CD90, and CD105, and lack of hematopoietic-related 
cells such as CD34, CD45, CD11b or CD14, CD19 or CD79D, 
and HLA-DR expression, and (c) their tri-lineage differ-
entiation potential into adipocytes, osteoblasts, and chon-
drocytes (Fig. 1) [4]. MSCs, which are present in adult tissues 
and organs such as adipose tissue, liver, kidney, heart, pla-
centa, amniotic fluid, amnion, and BM, among others, are 
undifferentiated cells that have the capacity to differentiate 
into a broad range of different cell types, including adipo-
cytes, neuron-like cells, osteocytes, chondrocytes, and other 
 
Figure 5 – Studies demonstrating that MSCs support leukemia development and 




In this context, several factors that are potentially released by MSCs (i.e. adhesion 
molecules, growth factors, cytokines, pro-angiogenic or immunomodulatory molecules) 
along with molecular alterations in the stromal cells within the BM have been reported to 
contribute to AML development 105. It has been demonstrated that osteoblast depletion 
enhanced MLL-AF9 AML cell proliferation and inhibited normal hematopoiesis in mice 
106. Likewise, a reduced number of NG2+ pericytes and a parallel increase of Nestin-GFP+ 
MSCs were observed within the BM of MLL-AF9 AML mice 107. Pasquier et al have 
shown that MSCs or ECs were able to transfer their cytoplasmic content (i.e. cytosolic 
molecules and organelles, including mitochondria) to AML cells by using filamentous 
actin-based structures forming tunneling nanotubes and in turn promoting the acquisition 
of chemoresistance 108. Recently, an increasing attention has been addressed to the role of 
extracellular vesicles (EVs) in leukemia development and progression. In particular, it has 
been demonstrated that MSC-EV may exert both pro- and antiangiogenic activities. 
Indeed, EVs derived from umbilical MSC have been shown to promote MSC migration 
and proliferation in vitro by activating the Wnt/beta-catenin 109 and the NF-κB pathway 110. 
Paradoxically, murine BM-MSC-derived exosomes, that are found to be enrich in miR-16, 
downmodulated VEGF in breast cancer cells 111.  
 
1.6 Immunomodulatory properties of MSCs 
 
Several in vitro and in vivo studies have demonstrated that MSCs can acquire 
immunomodulatory properties playing a crucial role in the maintenance of peripheral 
tolerance, in transplantation conditions, in autoimmunity and in tumor evasion (reviewed 
in 112,113). Two major actors involved in the regulation of immunomodulatory properties of 
MSCs are represented by IFN-γ and TNF-α that are crucial orchestrators of the 
immunosuppressive microenvironment 113.   
In vitro studies have shown that MSCs are able to negatively affect lymphocyte activation 
and proliferation. This effect required cell-cell contacts; indeed, it has been demonstrated 
that tranwell co-cultures of MSCs and peripheral blood mononuclear cell (PBMCs) did not 
prevent lymphocytes proliferation 114,115. Among the different soluble factors, a role for 
transforming growth factor-β (TGFβ) and hepatocyte growth factors has been 
demonstrated in suppressing the T cell proliferation 114,115. Moreover, also prostaglandin 
E2 (PGE2) and the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) 
114,115 have been reported to contribute to negatively regulate lymphocyte activities. 
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Regarding NKs, MSCs inhibit their proliferation and impair IFN-γ production, dampening 
their cytotoxic abilities and promoting anergy against target cells 112,116. Human NK 
proliferation along with CD56 expression and cytotoxicity were demonstrated to be 
partially reduced in vitro by hMSC PGE2 secretion, that conversely did not alter the 
expression of activatory receptors 116,117. Recently it has been shown that hMSCs deeply 
impact on T cell differentiation, promoting Treg expansion. In this context, Zhang et al 
stated that MSCs-derived exosomes induce Treg differentiation 118. In line with this, Court 
et al demonstrated that the artificial transfer of MSC-derived mitochondria induces Treg 
differentiation by up-regulating FOXP3, IL2RA, CTLA4, and TGF-β1 in T-cells 119. 
Moreover, MSCs interfere with dendritic cell (DC) differentiation, maturation, and 
function by releasing soluble factors such as IL-6, PGE2 and macrophage colony-
stimulating factor (M-CSF) that inhibit the secretion of IFN-γ and TNF-α by DCs and 
promote the release of IL-10 120-122.  
In vivo, outstanding results that functionally prove the immunosuppressive activity of 
MSCs was achieved in the treatment of graft-versus-host disease (GVHD) after allogeneic 
stem cell transplantation 123. Indeed, the systemic infusion of ex-vivo expanded MSCs was 
able to control lethal GVHD 123, although the mechanisms involved the immuno-
modulatory effects of MSCs remain a critical and unresolved question.  
 
1.7 AML and immune system 
 
The immunologic landscape is emerging as a crucial component of the leukemic BM 
microenvironment correlating with clinical parameters influencing not only the disease 
progression, but also the response to therapy 124. Although an increasing attention has been 
given to the immune infiltrate within the BM of AML patients, the alterations in frequency 
of functional T cells, that represents a pivotal requirement for the successful application of 
immunotherapies, has not been fully elucidated. Recently, some studies have demonstrated 
that the AML BM milieu differs from healthy BM as well as from other hematological 
malignancies 124-126. 
In particular, the AML microenvironment is characterized by immune cell dysfunction, an 
aberrant cytokine production and an increased ratio of suppressive cells. Indeed, since it 
has been reported that in patients the immune system is able to recognize and kill AML 
blasts, it is also well known that leukemic cells can set up different mechanisms to escape 
from host immune responses and bypass immune mediated elimination 125.  
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The major mechanisms of immunosuppression are represented by the up-regulation of 
negative checkpoint molecules including PD-L1 and TIM-3, an increase of arginase-2, the 
up-regulation of IDO1 and the expansion of MDSC and Treg cells or Th17 cells that are 
able to inhibit Th1 IFN-γ production 127. In this context, Sun et al described an increase of 
the MDSC frequency in the BM of AML patients and demonstrated that only in those 
patients achieving the complete remission, MDSC levels were significantly decreased after 
chemotherapy, while no differences were appreciated in the partial remission and non-
remission groups 128. Pyzer et al have shown that AML blasts are able to induce MDSCs 
via exosomal transfer 129. Indeed, in vitro, exosomes induce leukemic cells proliferation 
positively regulating cell cycle proteins 129. Regarding the T-cell compartment, it is widely 
known that a high frequency of Tregs in AML patients is associated with a poor disease 
prognosis 126. Tregs within the bone marrow of AML patients have been reported to 
suppress adoptively transferred cytotoxic T cell proliferation, limiting their in vivo 
expansion, thus contributing to AML progression 130. CTLA-4+ Tregs have been shown to 
contribute to tumor immune escape by dampening anti-tumor immune responses and 
down-regulating CD80/CD86 expression on antigen presenting cells 131. On the contrary, 
the role of PD-1 on Treg cells have remained to be clearly understood. Some studies have 
demonstrated that PD-1 deficiency induces proliferation and suppressive activity of Tregs, 
suggesting that PD-1 block may need to be applied carefully since it can interfere with 
Treg activities 132. Concerning Th17, their frequency has been found significantly higher in 
the peripheral blood and bone marrow mononuclear cells from AML patients compared 
with healthy donors. This phenomenon was associated with an increase of (IL)-17, IL-22, 
IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 in the plasma of patients, 
identifying these cytokines as major regulator of Th17 differentiation, as also confirmed by 
in vitro experiments 133. IL-17A, a signature cytokine secreted by Th17 cells was shown to 
induce the proliferation of AML cells that express IL-17 receptor positively regulating the 
activation of PI3K/Akt and Jak/Stat3 signaling pathway. In addition, the combination of 
IL-17A and IL-22 negatively impact on the generation of Th1 cells and the production of 
interferon (IFN)-γ from healthy donor or AML patient peripheral blood mononuclear cells. 
The increase of IL17 producing T cells also correlates with a poor prognosis, whereas 
patients with high Th1 cell frequency had prolonged survival 133.  
Sanchez-Correa et al. have also investigated the role of natural killer cells in AML 
progression demonstrating that the decrease of their frequency in the BM of patients 
correlates with a decreased overall survival 134. NK cell anti-tumor activity is regulated by 
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the interaction of MHC-I expressed on leukemia cells with inhibitory receptors that have 
been reported to be up-regulated in AML patients, resulting in an impairment of NK 
cytotoxic functions 135. NK cells are one of the major sources of IFNγ,  that is traditionally 
associated with anti-tumor/immune-activating responses 136,137. However, increased 
expression of IFN- γ and its associated genes have been unveiled in cancer cells and 
positively correlated with tumor invasion and with an unfavorable response due to the 
possible activation of immunosuppressive pathways, including the up-regulation of IDO1 
and the PD-1/PD-L1 axis 124,138, suggesting that IFN-γ may be involved also in tolerogenic 






Zinc finger E-box binding homeobox 1 (Zeb-1) is a zinc finger and homeodomain 
transcription factor that is also known as dEF1, ZFHX1A, Nil-2-a, TCF8, AREB6, or BZP. 
It belongs to the ZEB family that also accounts its homologous protein termed Zeb-2. ZEB 
factors display a high conservative structure across species 139 characterized by two C2H2-
type flanking zinc finger clusters that allow the interaction with paired CACCT(G) 140,141 
or CAGGT(G) 142 E-box-like promoter elements on DNA. Zeb-1 also contains binding 
sites for other proteins, such Smad interaction domain (SID), CtBP interaction domain 
(CID) and p300-P/CAF binding domain (CBD) through which it has been demonstrated to 
interact with co-repressors or co-activators 140,141(Figure 6).  
 
 
Figure 6 – The schematic structure of ZEB1/2 158 
 
 
Its expression can be accomplished either at transcriptional or post-transcriptional levels. 
One of the most known mechanism of regulation is represented by the feedback loop 
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cells [17], indicating that ZEB1 is not only involved in the 
oncogenesis and development of cancers but also affects 
the prognosis of cancer patients. This review will focus 
on the EMT transcription factor ZEB1 and its functions 
in the oncogenesis and development of breast cancer.
Transcription factor ZEB1 and its structural 
characteristics
ZEB homeobox is a transcription factor family that 
includes ZEB1 (also known as TCF8 and δEF1) and 
ZEB2 (also known as SIP1) [18]. Both of them con-
tain  C2H2-type zinc fingers, the common DNA-binding 
motifs binding to paired CAG GTA /G E-box-like ele-
ments in the promoters of their target genes, and regulate 
cell differentiation and tissue-specific functions [19, 20]. 
ZEB1 is located on Chr10p11.22 and encodes the 1117 
amino acid ZEB1 protein, which mainly consists of the 
homologous structural domain homeodomain (HD) in 
the middle of the structure and the structures of the zinc 
finger N-terminal cluster (NZF) and C-terminal cluster 
(CZF) on both sides (Fig. 1).
The expression pattern of ZEB1 in breast cancers 
and its molecular mechanism of transcriptional 
suppression
The expression of ZEB1 in breast cancer
The exp ession level of ZEB1 is increased in triple-nega-
tive breast cancers (TNBCs) and basal-like breast cancers 
compared to the luminal subtype [21]. To understand 
the role of ZEB1 in TNBCs, Lehmann et  al. compared 
the different gene expression levels between aggres-
sive TNBC cancer cells (MDA-MB-231) with high ZEB1 
levels and t eir c rresponding ZEB1 knockdown cells, 
revealing that the expressio  of 60% f genes was upreg-
ulated fter ZEB1 knockdown and that the remaining 
genes were downr gulated [22]. They predicted poten-
tial direct or indirect target genes of the transcriptional 
repressor ZEB1 and suggested that abnormal expres-
sion of the gene set may be a predictor of poor survival, 
therapy resistance and increased metastatic risk in breast 
cancer [22].
ZEB1 functions as a transcriptional suppressor
As mentioned before, the main transcriptional function 
of ZEB1 is suppressing the expression of its target genes, 
such as epithelial markers (E-cadherin), and correspond-
ingly increasing the mesenchymal levels of vimentin and 
N-cadherin [23]. Eger et al. first reported ZEB1 as a direct 
transcriptional repressor of E-cadherin by physically 
binding to the proximal promoter of E-cadherin in breast 
cancers [10]. As a transcriptional repressor, it was iden-
tified that ZEB1 can also directly bind to the promoter 
of miR-190, resulting in transcriptional suppression of 
miR-190 expression, which can reverse the transforming 
growth factor (TGF)-β-induced EMT process [24]. Most 
importantly, the expression of the miR-200 family mem-
bers was suppressed by ZEB1 binding to their promoters 
and was conversely involved in the regulation of ZEB1 
levels as a reciprocal ZEB1/miR-200 feedback loop [25, 
26].
A various set of cofactors were also recruited during 
the transcriptional suppression process of ZEB1 for its 
downstream target genes [27, 28], although only a few of 
them were reported [29]. ZEB1 activation requires inter-
action with PC2-CtBP-LSD1-LCoR or the yeast mating-
type switching/sucrose non-fermenting (SWI/SNF) 
chromatin-remodeling protein BRG1 to form the ZEB1-
Smad3-p300-P/CAF complex, affecting general tran-
scription [28]. The effector of the Hippo/Yes-associated 
protein (YAP) pathway, YAP, can specifically and directly 
interact with ZEB1, converting ZEB1 from a transcrip-
tional repressor to a transcriptional activator that binds 
to conserved TEAD-binding sites. As a result, functional 
cooperation between ZEB1 and YAP can stimulate the 
transcriptional activities of a ‘common ZEB1/YAP target 
gene set’, such as connective tissue growth factor (CTGF) 
and AXL receptor tyrosine kinase (AXL) [22].
Usually, the functional statuses of chromatin are 
identified by the covalent modification pattern of the 
N-terminal domains of the histones, indicating the tran-
scriptional activity of their target genes. For example, his-
tone H3 lysine 4 trimethylation (H3K4me3) was reported 
to be associated with transcriptional initiation [30], while 
lysine 79 dimethylation (H3K79me2) was associated with 
promoting transcriptional elongation [31]. Overall the 
combined effect of H3K4me3 and H3K79me2 contributes 
to the activation of gene transcription. In addition, lysine 
27 trimethylation (H3K27me3) was suggested to contrib-
ute to transcriptional repression [32–35]. An innovative 
and interesting study found that luminal breast cancer 
cell lines exhibited only presence of H3K27me3 and the 
relative absence of 3K4me3 and H3K79me2 at the ZEB1 
Fig. 1 The schematic structure of ZEB1/2. The structures of ZEB1/2 
are similar, with N-terminal and C-terminal zinc finger (NZF and CZF) 
and a central Homeodomain (HD). The ZEB1/2 protein interacted 
with other proteins through a corresponding binding domain, 
including the CAF/p300 binding domain (CBD) at the N-terminal, 




between Zeb-1 and miR-200 family which represses both Zeb-1 and Zeb-2 to maintain 
epithelial states 143. On the contrary, well-described positive regulators are represented by 
TGF-β, Wnt/ β -catenin, NF-κB, PI3K/Akt and Ras/Erk pathways 144-146. In this context, 
ZEB1 represents the direct downstream target of the Wnt canonical signalling in lung 
cancer and its activation leads to the decrease of epithelial genes, including E-cadherin 147. 
In parallel, TGF-β induces Smad2 phosphorylation and activates ZEB1-dependent 
signaling, resulting in an enhanced invasiveness of glioblastoma cells 148. In addition, 
TGF-b is able to induce epithelia-to-mesenchymal transcription (EMT) of breast cancer 
cell lines on one hand up-regulating Zeb-1 levels and concomitantly suppressing miR-
200a, miR-200b, miR-200c, miR-141 and miR-429 expression 149. Moreover, the 
activation of ERK/MAPK-ZEB1 axis by the hepatocyte growth factor in a model of 
prostate cancer increases the metastatic potential of tumor cells 150.  
ZEB1 has been firstly characterized as a major regulator of cell differentiation given its 
role during embryogenesis, cell differentiation in cartilage, bone and the regulation of 
hematopoietic compartment homeostasis and only later recognized for its role in cancer 
progression 141. In this context, several studies performed in mouse models and in humans 
demonstrated that ZEB1 expression can drive EMT by the simultaneous repression and 
activation of epithelial and mesenchymal genes 151,152, inducing a more aggressive 
phenotype 153. More recently, accumulating evidences suggest that besides being a key 
contributor of cancer cell metastasis, ZEB-1 is also involved in the regulation of immune 




Although its role in cell differentiation, immune cell polarization and its pro-tumoral 
properties in solid cancers, the activity of this transcription factor in hematological 
malignancies has been largely overlooked because of the perceived lack of relevance in 
non-EMT contexts. In particular, the mechanisms trough which ZEB1 can contribute to 
leukemia development and pathogenesis remain to be elucidated. 
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1.8.1 Zeb-1 in solid tumours 
 
ZEB family members have been firstly recognized as key factors regulating embryonic 
development and cell differentiation 154. Indeed, Zeb-1 -/- mice die close to the birth due to 
widespread skeletal abnormalities 155. Based on these observations, in the past decades an 
increasing interest has been addressed to the possible role of Zeb-1 in determining cellular 
functions and states. In this context, several studies demonstrated a crucial role for Zeb 
proteins in regulating cell proliferation, response to DNA damage, and cell survival, with a 
ZEB1 is sufficient for triggering tumor initiation, whereas fur-
ther induction is necessary for promoting metastasis (12).
Beyond malignant transformation, ZEB1 expression was also
shown in lung and pancreatic cancer cells to be a determinant
of K-RAS addiction, the epithelial differentiation state of
K-RAS–mutant cells being associated with dependency on the
mitogenic oncogene to maintain cell survival (24). Important-
ly, the oncogenic activities of ZEB1 are not restricted to epi-
thelial cells. As an illustration, ZEB1 cooperates with BRAFV600
in promoting transformation of immortalized melanocytes,
and its depletion impairs or delays BRAFV600-induced tumor-
igenesis in nude mice upon xenografting (5). Interestingly,
ZEB2 displays an opposite pattern of expression in the course
of melanocytic transformation and acts as tumor suppressor in
these cells (5).
ZEB1, Cancer Stem Cells, and Genetic
History of Tumorigenesis
The initial observation that, after EMT, transformed human
mammary epithelial cells acquire stem-like features led us and
others to propose that EMT commitment generates cancer stem
cells (CSC; refs. 25, 26). CSCs are characterized by two major
properties: the ability to self-renew and the capacity to regenerate
the phenotypic heterogeneity of the parental tumor (27). These
cells, that are believed to sustain primary tumor growth and to
drive the seeding and establishment of metastases at distal sites,
generally represent a minor fraction of the whole cancer cell
population. Whereas CSCs were general y thought to reside at
the apex of a unidirectional neoplastic cell hierarchy, the func-
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Figure 1.
Oncogenic functions of the EMT-inducing transcription factor ZEB1. The ZEB1 transcription factor is a central determinant of cell fate. It transcriptionally
regulates factors involved in the control of cell differentiation, proliferation, survival, and motility. Its expression fosters the tumorigenic process from the
earliest steps, including malignant transformation, and provides cancer cells with migratory and invasive capabilities. Over the course of tumor development,
ZEB1 has a profound impact on cancer cell plasticity and intratumor genetic and epigenetic heterogeneity. ZEB1 also promotes an escape from the immune
control in the context of an intricate cross-talk with immune cells and finally contributes to resistance to treatments. CTC, circulating tumor cells; MET,
mesenchymal-to-epithelial transition; MDSC, myeloid-derived suppressor cells.
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dramatic impact on tumor development, from early steps of tumorigenesis to cancer 
progression 153.   
In particular, in solid tumors, it has been demonstrated that Zeb-1 expression is induced by 
multiple pathways that can be involved in its activation, including WNT 146, NF-kB 144, 
cyclooxygenase-2 (COX-2) 156 and hypoxia-inducible factor-1 (HIF-1) signalling 157, 
stressing the correlation between Zeb-1 expression and an enhanced cellular motility and 
with the acquisition of stemness and proliferative properties 158,159. Moreover, in different 
solid malignancies, including breast cancer, lung cancer and pancreatic cancer, colon 
cancer and osteosarcomas, Zeb-1 aberrant expression is involved in the induction of EMT 
related programs that are associated with an increased aggressiveness, metastatic behavior, 
onset of resistance to therapy and poor outcome 160.  
High levels of Zeb-1 are observed in a significant fraction of human in situ pancreas 
adenocarcinoma. These results are also corroborated by in vivo studies, that showed Zeb1 
over- expression in noninvasive pancreatic lesions 161. In line with this, Zeb-1 decreased 
expression in K-ras mutant mice is associated with a reduction in both the number and 
grading of acinar ductal metaplasia and pancreatic intrae- pithelial lesions (PanINs), 
highlighting the role of Zeb-1 in the early steps of pancreatic tumorigenesis 162. In lung 
cancer, Zeb-1 activates phosphatidylinositol 3-kinase (PI3K) by derepressing miR-200 
targets inducing an EGFR/ERBB2 autocrine loop and enhancing GATA3-induced 
expression of the p110α catalytic subunit of PI3K in turn promoting the invasive and 
metastatic propensities of tumor cells 163. In a model of breast cancer, Zeb-1 silencing 
suppresses the ubiquitin ligase CUL4A-driven proliferation also reducing EMT, 
tumorigenesis, and metastasis 164. In addition, in human breast cancer cell lines, it has been 
demonstrated that Zeb-1 silencing leads to the up-regulation of more than 200 genes and to 
the down-regulation of 30 genes involved in cell adhesion and epithelial differentiation 
165,166. Lehmann et al have recently pointed out the clinical relevance of Zeb-1 levels, 
describing a direct interaction between Zeb-1 and Yes-associated protein (YAP), a protein 
effector of the Hippo pathway. In particular, in a cohort of hormone receptor-negative 
breast cancers, they showed a positive correlation between Zeb-1/YAP1 expression with a 
peculiar gene set that has been correlated with worse survival, therapy resistance and 
increased metastatic risk 160.  
Several studies have also suggested a close correlation between EMT and stemness; 
indeed, after EMT, human mammary epithelial cells acquire stem-like features 167,168. In 
line with this, Weinberg et al demonstrated that the release of TGFβ by tumor 
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microenvironment activated Zeb-1 that inhibits the expression of stemness-repressing 
miRNAs, including miR-200, but also of miR-183 and miR-203, which together target 
BMI1 and in turn promoted the transition from non-cancer stem cells (CSCs) to CSCs169. 
Accordingly, it has been shown that Zeb-1 expression in normal human mammary stem 
cells is able to trigger antioxidant programs mainly driven by the methionine sulfoxide 
reductase MSRB3 that protects stem cells against the oxidative stress 170. In breast cancer, 
Zeb-1 expression is up-regulated by cyclin-dependent protein kinase-like 2 (CDKL2) that 
is able to activate a positive feedback circuit promoting β-catenin signaling pathway 
enhancing the mesenchymal characteristics and stem cell-like properties 171,172.  
Moreover, Zeb-1 expression levels has been associated with an increased resistance to 
therapy. Indeed Wang et al. found that high ZEB1 levels are associated with a poor 
response to epirubicin in breast cancer patients. Likewise, in a large cohort of human 
breast cancer subjects, high levels of Zeb-1 correlate with an increase of Bcl-xl and cyclin 
D1, predicting a poor response to chemotherapy 173. Molecularly, chemotherapy resistance 
is mainly due to an activation of the DNA repair system due to the activation of 
ZEB1/p300/ PCAF (P300/CBP-associated factor, PCAF) complex that activated ATM in 
turn promoting homologous recombination-mediated DNA damage response to clean up 
the chemotherapy-induced DNA fragments 173. Zeb-1 expression also confers anti-estrogen 
resistance in breast cancer. Indeed, Zeb-1 is reported to form a complex with DNMT3B 
and HDAC1 that silences the estrogen receptor (ER)-α promoter, subsequently attenuating 
the responsiveness of breast cancer cells to antioestrogen treatment 174. Bai et al. 
demonstrated that miR-200c suppressed the transcription factor ZNF217, a positive 
regulator of TGF-β/Zeb-1, increasing trastuzumab sensitivity and suppressed the invasive 
abilities of breast cancer cells 175.   
 
1.8.2 Zeb-1 in the immune system 
 
Even if Zeb-1 expression has been primarily studied in cancer cells due to its role in the 
promotion of survival, proliferation and stemness, in recent years several studies have 
focused on the hematopoietic compartment, and it is now clear that most of the cells of 
myeloid as (Figure 8) well as lymphoid origin (Figure 9) express Zeb-1 or Zeb-2. In these 
cells (including dendritic cells, macrophages, monocytes, B, T, and NK cells) Zeb factors 




In particular, concerning Zeb-1 expression in myeloid cell lineage, it has been reported that 
it is primarily expressed by DCs, macrophages and neutrophils 176 even if its function in 
granulocytes has yet to be understood. In DCs, Zeb-1 expression is not confined to a 
particular subset as demonstrated by RNA seq results 176. Smita et al demonstrated that toll 
like receptor (TLR) 9 stimulation increases Zeb-1 levels and subsequently the production 
of il-6, il-10 and il-12, in turn controlling immunogenic responses of CD8α+ conventional 
Type-I DCs (cDC1) 177. Indeed, co-culture of Zeb1-deficient MutuDCs with CD4+ T 
helper cells skewed their differentiation toward Th2 subtype rather than a Th1 177.  
Importantly, a recent study by Cortes at al investigated the expression of Zeb-1 in normal 
and tumor-associated macrophages (TAMs) showing that its expression is crucial for their 
polarization toward a pro-tumor phenotype 178. Indeed, Zeb-1 directly induces ccr2 and 
positively regulates the expression of Cxcl15, Cd163, Mrc1, mmp9, il-10, Nfkb1/p50, vegf 








Figure 8 – Zeb-1 and Zeb-2 expression in murine myeloid cells (adapted from 176) 
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fewer cDC2s originating from Zeb2!/! versus Zeb2+/+ BM in a competitive BM chimera setting
[7,14]. One possible explanation for this is that ZEB2 may not regulate the entire cDC2 lineage,
but instead regulates an undefined subset (Figure 3 and Box 1), although this remains to be
tested. Fitting with this idea, the impact of Zeb2 deficiency (in terms of cDC2 numbers) varied
between tissues in this study. For example, in the liver, Zeb2 deletion resulted in fivefold fewer
cDC2s relative to WT controls, but only a 1.5-fold and 2.5-fold reduction in the spleen and lung,
respectively [14]. Moreover, when cDC2s in the small-intestine lamina propria were further
subdivided based on CD103 expression, only the CD103! cDC2s were found to partially
depend on ZEB2, being reduced in numbers in Zeb2-deficient mice compared with WT
Zeb1
Zeb2
(A) Myeloid cells microarray data
Zeb1
Zeb2





(C) Lymphoid cells microarray data
Zeb1
Zeb2
Figure 2. ZEB Expression in the Murine Immune System. For illustrative purposes in this review, a heatmap is
shown detailing relative transcript expression levels of Zeb1 and Zeb2 across mouse immune cells. Data are a compilation
of that generated by the ImmGen Consortium (www.immgen.org) or in-house [14,25,35]. Microarray and bulk RNA-Seq
data were processed separately. Microarray: data were analyzed using the limma R package (Bioconductor). The robust
multi-array average (rma) procedure was used to normalize data within arrays (probeset summarization, background
correction, and log2 transformation) and between arrays (quantile normalization). Only probesets that mapped uniquely to
one gene were retained, and for each gene the probeset with the highest expression level was retained. Bulk RNA-Seq:
normalization was performed using the calcNormFactors function of the edgeR package (Bioconductor) with default
parameters. Normalized counts were subsequently transformed to log2 values using the voom function of the limma R
package. Values shown were obtained by calculating the mean expression per gene and subtracting this from each log2-
normalized value of that gene. Separate heatmaps were created for microarray and bulk RNA-Seq data. Both heatmaps
use the same color legend.
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(Figure legend continued on the bottom of the next page.)
Role of ZEBs in Murine Myeloid Immune Cells. Myeloid immune cells develop primarily in the bone marrow
from HSCs, and subsequently migrate into the blood and tissues where they exert their functions or further differentiate into
mature cells which then carry out their specific roles. The main exceptions to this are tissue-resident macrophages that
primarily develop from either yolk-sac macrophages or fetal liver monocytes during embryogenesis, with a contribution
from BM monocytes in adulthood in some tissues such as the gut and skin. The role of ZEBs in this differentiation process
and in the maintenance/function of mature myeloid cells has recently begun to be elucidated, and demonstrated roles (red
font) for ZEB2 have been identified in monocytes, pDCs, cDCs, and macrophages. On the one hand, ZEB2 must be absent
for cDC1 development, and is downregulated from CDP to pre-cDC1 to cDC1 stages. On the other, ZEB2 is required by
434 Trends in Immunology, May 2019, Vol. 40, No. 5
Introduction 
 28 
expression was enhanced in Zeb-1 knock-down (KD) memory CD8+ T cells 143. In this 
context, ChIP-qPCR studies showed that Zeb-1 directly binds the murine Zeb-2 promoter 
in naïve CD8+ T cells repressing its expression 143. 
appears to be inversely regulated [55] (Figure 4). Naïve CD8+ T cells express high Zeb1 that
decreases following T cell activation, and which is then upregulated again in memory T cells
[55]. Eight days following acute LCMV-Arm infection, murine MP T cells exhibited increased
expression of Zeb1 relative to TE T cells, in a reciprocal manner to Zeb2 [55]. Similarly, Zeb1
expression was increased in Zeb2-deficient bulk effector CD8+ T cells relative to WT controls,
and Zeb2 expression was elevated in Zeb1-deleted memory CD8+ T cells, suggesting that
ZEB1 and ZEB2 might repress the expression of each other. Accordingly, ChIP-qPCR dem-
onstrated direct ZEB1 binding to the murine Zeb2 promoter in WT naïve CD8+ T cells, although
direct ZEB2 binding to ZEB1 could not be confirmed because a ZEB2 antibody was unavailable
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Figure 4. ZEB-Mediated Regulation of Murine Lymphocyte Differentiation States. Although ZEB2 is crucial for
murine B cell development in the bone marrow, it is primarily the mature lymphocytes that depend on ZEB transcription
factors (TFs) to regulate the acquisition and maintenance of distinct cellular states at steady-state or following infection (e.
g., viral; lymphocytic choriomeningitis virus, LCMV). ZEB TFs have a demonstrated (red font) or speculated (blue font) key
role in modulating the differentiation of most lymphocyte populations. Abbreviations: CLP, common lymphoid progenitor;
GC, germinal center; HSC, hematopoietic stem cell; NK cell, natural killer cell; TFH, T follicular helper cell; Treg, T regulatory
cell.
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1.8.3 Zeb-1 in leukemia 
 
Over the past decades, a growing interest has been addressed to the role of Zeb-1 in the 
control and promotion of hematologic malignancies. Indeed, even if the role of EMT-
related proteins has been largely overlooked, recently it has been shown that the 
deregulation of such factors deeply influences leukemia development and pathological 
features142,183,184 . In particular, in vitro and in vivo studies suggest that Zeb-1 and Zeb-2 
transcription factors are able to exploit an oncogenic or oncosuppressive function 
depending on the lineage (Figure 10) (reviewed in 142).  
  
 
Figure 10 – Zeb-1 and Zeb-2 role in the promotion of hematologic malignancies142. 
 
In T-cell acute lymphoblastic leukemia (T-ALL) ZEB1 seems to act as a tumor suppressor. 
Indeed, mutant mice displaying Zeb-1 impaired functions showed defects in lymphocyte 
maturation developing T-cell lymphoma/leukemia with a median onset of 6 months185,186. 
Hidaka et al have demonstrated that in T-ALL cells Zeb-1 expression is often dysregulated 
by several mechanisms, including chromosomal translocations with heterozygous deletion, 
intragenic mutations or epigenetic mechanisms and its downregulation is associated with a 
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resistance to TGFβ-mediated growth arrest 187,188. In this context, Zeb-1 forms a complex 
with Smad3 and Smad7 that is activated by TGFβ. This complex binds Smad-responsive 
elements of the p21(CDKN1A) promoter inducing its transcription 188.  
In B-cell malignancies, an altered Zeb-1 expression is observed in mantle cell lymphoma 
(MCL) and diffuse large B-cell lymphoma (DLBCL). In particular, the constitutive 
activation of Wnt/ β-catenin signaling in MCL with is associated with the concomitant 
high expression of Zeb-1 that supports tumor growth capacity, promotes chemotherapy-
resistance by increasing the expression of drug influx/efflux transporters 189. In DLBCL, a 
strong Zeb-1 activation was associated with an adverse 3-year overall survival of patients 
compared to those with low Zeb-1 levels 190. Accordingly, patients expressing high mir-
200 levels that, as discussed before represents a negative regulator of Zeb-1, results in a 
less aggressive behaviour of this disease 191. 
Concerning myeloid malignancies, recently, Stavropoulou et al have highlighted the key 
role of Zeb-1 in the regulation of adhesion and invasion of long-term-hematopoietic stem 
cells (LT-HSC)-Early-AML blasts. By using an inducible MLL-AF9-driven AML mouse 
model they showed that the knockdown of Zeb-1 in leukemic cells significantly impaired 
their migration and invasion abilities in-vitro and compromised cell infiltration in the bone 
marrow and other organs in in-vivo studies 184.  
 
1.9 CD40  
CD40 receptor is a 48-kDa type I transmembrane protein, belonging to the TNF receptor 
(TNFR) superfamily and is encoded by the gene located on the q arm of chromosome 20 
192. It is formed by 193 amino acid extracellular domain, 21 aa leader sequence, 22 aa 
transmembrane domain, and a 62 aa intracellular domain in human (90 aa in mouse) 193. Of 
note, in the extracellular domain of CD40, there are 22 cysteine residues that are conserved 
between the members of the TNFR superfamily 193.  
CD40 expression has been primarily associated to B cells and professional antigen-
presenting cells, such as DCs. CD40 binds its ligand CD40L, which is transiently 
expressed on T cells and other non-immune cells under inflammatory conditions 194. The 
activation of CD40/CD40L on the surface of dendritic cells promotes cytokine production, 
the induction of costimulatory molecules on their surface facilitating the cross-presentation 
of antigen 194.  
Molecularly, CD40 triggering by CD40L leads to the trimeric clustering of CD40 and the 
recruitment of TNFR-associated factors (TRAFs) adapter proteins. In particular, the 
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cytoplasmic domain of CD40 contains two binding sites, a proximal one for TRAF6 and 
two distal sites that bind TRAF1, TRAF2, TRAF3 and, indirectly, TRAF5. TRAFs 
interaction activates a wide number of well-characterized signal transduction pathways, 
including the nuclear factor-κB, p38 mitogen-activated protein kinase, c-Jun-NH2-kinase 
(JNK), Janus kinases (JAKs) and PI3K pathways. Moreover, CD40 can also activate 
directly JAK3 in a TRAF-independent manner inducing the phosphorylation of signal 
transducer and activator of transcription 5 (STAT5) 194.  
 
1.9.1 CD40 expression by stromal cells  
More recently it has been demonstrated that CD40 can also be expressed by non-immune 
cells, including stromal cells (fibroblasts, endothelial cells and MSCs) and tumors. Fries et 
al were the first to demonstrate that human fibroblasts up-regulated CD40 expression in 
response to IFN-γ stimulation 195. Accordingly, Gelbmann et al showed that primary 
colonic lamina propria fibroblasts increased the expression of CD40 and the CD40/CD40L 
binding induce IL-8, IL-6, or monocyte chemotactic protein 1 (MCP-1) secretion due to 
the activation of NFκB pathway 196. Moreover, it has been reported that in endothelial cell 
CD40 expression can be modulated by the proinflammatory cytokines such, TNF-α, IL-1 
and IFN-γ, and by bacterial lipopolysaccharide (LPS) 197. Déchanet et al have also 
demonstrated that CD40 triggering leads to the release of pro-inflammatory cytokines (IL-
6 and granulocyte-macrophage colony-stimulating factor (GM-CSF)) involved in 
leukocyte recruitment and enhanced the expression of several adhesion molecules, i.e. 
CD54, CD62E and CD106 198,199. 
CD40 engagement by CD40L on human aortic endothelial cells can increase CX3CL1 
protein levels and induces TNF-α production 200. 
In line with these findings, the relevance of CD40 expressed by MSCs in haematological 
malignancies has been highlighted by Franco G et al 201who demonstrated that also BM 
MSCs are able to up-regulates CD40 expression in response to particular conditions 201. 
Indeed, in this study performed in mouse models and human samples it has been 
previously shown that MSCs derived from splenic marginal zone lymphoma patients 
expressed CD40 that promotes a pro-inflammatory loop with mast cells in turn sustaining 
tumor cell growth, suggesting that CD40 expression by MSCs can regulate immune cells 
within the microenvironment sustaining the progression of haematological neoplasms 201. 
Furthermore, it has been pointed out that the CD40 expression by MSCs can be used as an 
independent predictor of PFS in splenic marginal zone lymphoma (SMZL) cases 201. 
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Indeed, patients expressing high stromal levels of CD40 showed a mean PFS of 16.9 
months (compared with 41.2 months for CD40low patients) and unfavorable clinical 
features such as low hemoglobin levels and elevated β2 microglobulin 201. 
All these studies suggested that CD40 expression on stromal cells influences their 
immune-regulatory properties and play a crucial role in the regulation of inflammatory 
responses and immune landscape, shedding a new light on its possible involvement in the 
promotion of the tolerogenic environment that can sustain the development and 
progression of haematological malignancies including leukemia.
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2 AIM OF THE STUDY 
 
This thesis evaluated the contribution of clone- and microenvironment-intrinsic 
mechanisms that are involved in the induction of immune tolerance/suppression in 
the context of AML. In particular we focused our attention on two molecular drivers 
expressed by leukemic cells or BM-MSC respectively represented by Zeb-1 and 
CD40 and we aimed at unveiling their role in AML development and progression.  
We foresee two possible scenarios (Figure 11): 
•  Leukaemia cells autonomously create an immunosuppressive environment via 
clone-intrinsic mechanisms including the activation of EMT-related programs 
(i.e. Zeb-1). Herein, Zeb-1 can serve as the key molecular link between EMT- 
and immunosuppression- related programs and may functionally regulate 
mesenchymal and AML clone suppressive activity.  
•  BM-mesenchymal cells can promote active tolerance by expressing co-
stimulatory molecules, such CD40, influencing the T-cell status and creating an 
















Figure 11 - Hypothesis of the study
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3. MATERIALS AND METHODS 
 
 
3.1 Global gene expression profiling (GEP) and bioinformatics 
 
61 AML and 7 healthy donors (HD) samples were analysed, and their characteristics are 
summarized in Table 1A.  
Samples were obtained from AML patients and healthy donors after written informed 
consent, as approved by the institutional ethics committees (Comitato Etico 
Indipendente di Area Vasta Emilia Centro, protocol 112/2014/U/Tess and Comitato 
Etico della Romagna, protocol 5805/2019), in accordance with the Declaration of 
Helsinki.  
Array data from 61 AML bone marrow samples have been generated by the Next 
Generation Sequencing platform for targeted Personalized Therapy of Leukemia (NGS-
PTL) project. 
Data quality control and normalization (signal space transformation robust multi-array 
average) of NGS-PTL data (Affymetrix Human Transcriptome Array 2.0) were carried 
out by Expression Console software (version 1.4.1, Affymetrix, Thermo Fisher 
Scientific). Expression profiles of NGS-PTL data have been recently deposited in the 
Gene Expression Omnibus (GEO) repository with accession number GSE161532.  
For public gene expression datasets, including GSE6891 (N= 461 blood or bone 
marrow samples of acute myeloid leukemia patients; Affymetrix U133 Plus 2.0 array) 
and GSE37642 (N=562 of adult patients with acute myeloid leukemia; Affymetrix 140 
HGU-133plus2; 422 HGU-133A; 422 HGU-133B), data were normalized by 
Transcriptome Analysis Console Software (version 4.0.1) using robust multi-array 
average normalization. In addition, a public dataset with 11 paired peripheral blood 
samples obtained at the times of diagnosis and relapse with cytogenetically normal 
AML was analysed (GSE66525) 202. 
The Beat AML 203 and The Cancer Genome Atlas (TCGA) project on AML 204  
transcriptomic cohorts were obtained from https://portal.gdc.cancer.gov (projects 
BEATAML1.0-COHORT and TCGA-LAML), respectively. The datasets used in the 
thesis are described in Table 1B.  
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  NA= not available; t-AML=therapy related AML; sec= secondary  
 
Table 1A. Patients’ characteristics NGS-PTL cohort (continue) 
 









1 FEMALE AML de_novo dx BM 54 other intermediate NA 38,9
2 MALE AML de_novo dx BM 66 other intermediate M4 115
3 FEMALE AML de_novo dx BM 68 other adverse NA 8,6
4 MALE AML de_novo dx BM 57 normal intermediate M4 2,9
5 FEMALE AML de_novo dx BM 59 normal intermediate M2 1,6
6 FEMALE AML NA dx BM NA normal intermediate NA NA
7 FEMALE AML t-AML dx BM 74 complex adverse M5 2,8
8 MALE AML de_novo dx BM 65 other intermediate NA 46,5
9 FEMALE AML t-AML dx BM 76 other intermediate NA NA
10 FEMALE AML NA dx BM 69 complex adverse M4 NA
11 FEMALE AML de_novo dx BM 51 normal intermediate M0 3,8
12 FEMALE AML de_novo dx BM 47 normal intermediate M2 89,4
13 MALE AML de_novo dx BM 67 normal intermediate M4 9,7
14 FEMALE AML NA dx BM 42 normal intermediate NA 14,5
15 MALE AML sec dx BM 71 normal intermediate NA 2,3
16 FEMALE AML de_novo dx BM 70 other intermediate M4 NA
17 MALE AML de_novo dx BM 82 other intermediate NA NA
18 MALE AML t-AML dx BM 69 complex adverse M5 238
19 MALE AML de_novo dx BM 62 complex adverse M0 1,5
20 FEMALE AML de_novo dx BM 67 normal intermediate M0 108,6
21 MALE AML NA dx BM NA other adverse NA NA
22 MALE AML t-AML dx BM 62 complex adverse NA 2,7
23 MALE AML NA dx BM NA complex adverse NA NA
24 MALE AML de_novo dx BM 39 t(8;21) favorable M2 NA
25 FEMALE AML de_novo dx BM 62 MLL-rearranged intermediate M5 23,1
26 FEMALE AML de_novo dx BM 50 normal intermediate M5 77,7
27 FEMALE AML NA dx BM 76 normal intermediate NA NA
28 FEMALE AML de_novo dx BM 60 normal intermediate NA 68,5
29 FEMALE AML t-AML dx BM 62 other intermediate M1 13,4
30 MALE AML de_novo dx BM 66 normal intermediate M4 18,9
31 MALE AML de_novo dx BM 42 normal intermediate NA 163,9
32 MALE AML de_novo dx BM 45 normal intermediate M5 88
33 FEMALE AML de_novo dx BM 66 normal intermediate NA 35,9
34 FEMALE AML de_novo dx BM 60 normal intermediate M1 3,2
35 FEMALE AML de_novo dx BM 72 normal intermediate NA 26,1
36 FEMALE AML de_novo dx BM 34 normal intermediate M1 102
37 FEMALE AML de_novo dx BM 38 normal intermediate M1 37,2
38 FEMALE AML NA dx BM NA complex adverse M2 NA
39 MALE AML de_novo dx BM 61 inv(16)/t(16;16) favorable M4 7,4
40 FEMALE AML de_novo dx BM 71 other intermediate M4 90
41 FEMALE AML t-AML dx BM 62 complex adverse NA 77
42 MALE AML t-AML dx BM 68 other adverse M0 5,2
43 MALE AML de_novo dx BM 42 other intermediate M5 66,9
44 MALE AML de_novo dx BM 64 normal intermediate M1 1,9
45 MALE AML de_novo dx BM 64 normal intermediate M1 189,5
46 MALE AML de_novo dx BM 77 normal intermediate NA 6,7
47 FEMALE AML sec dx BM 66 normal intermediate NA NA
48 MALE AML de_novo dx BM 64 normal intermediate M1 65,1
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49 MALE AML de_novo dx BM 70 normal intermediate NA 234
50 MALE AML NA dx BM NA normal intermediate NA NA
51 FEMALE AML t-AML dx BM 57 inv(16)/t(16;16) favorable M4 10,5
52 FEMALE AML de_novo dx BM 72 other intermediate M2 35,1
53 MALE AML de_novo dx BM 31 t(8;21) favorable M4 5,1
54 MALE AML de_novo dx BM 67 complex adverse M2 3,6
55 MALE AML de_novo dx BM 52 t(8;21) favorable NA NA
56 MALE AML sec dx BM 66 other intermediate NA 9,6
57 FEMALE AML de_novo dx BM 39 other intermediate M1 43,2
58 MALE AML de_novo dx BM 73 normal intermediate NA 2
59 FEMALE AML de_novo dx BM 67 normal intermediate NA 46,7
60 MALE AML sec dx BM 66 normal intermediate NA 3,9
61 FEMALE AML de_novo dx BM 63 normal intermediate M2 44,3
  
Table 1A. Patients’ characteristics NGS-PTL cohort 
 
 
ID Gender Age	(years) risk
HD01 Male 43 /
HD02 Female 62 /
HD03 Male 19 /
HD04 Male 57 /
HD05 Male 49 /
HD06 Male 27 /
HD07 Female 53 /    
Table 1A. Healthy donors’ characteristics  
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Table 1B. Datasets used in the manuscript 
 
 
3.2 Cell cultures and chemicals 
The C1498 cell line, a murine AML cell line isolated from a leukemic 10-month-old 
C57BL/6 (H-2b) female mouse in 1941 205 was purchased from ATCC, while WEHI-3B 
murine myelomonocyte cell line syngeneic in BALB/c mice was from Sigma Aldrich. 
Cells were respectively cultured in DMEM ((Dulbecco's modified Eagle's medium) and 
RPMI-1640 (Thermo Fisher Scientific) supplemented with 10 % fetal bovine serum 
(FBS; Thermo Fisher Scientific), 1 % antibiotics (Thermo Fisher Scientific), 2 mM 
glutamine, 1 mM sodium pyruvate, 1 mM HEPES and 1X Minimum Essential Medium 
(MEM) Non-Essential Amino Acids Solution, in a humidified atmosphere containing 5 
% CO2 at 37°C.  




3.3 Stable gene-silencing 
 
Lentiviral Particles (OriGene Technologies, cat number TL501051V) were purchased 
from OriGene Technologies. To knockdown Zeb-1 in C1498, 104 cells were treated 
overnight with lentiviral particles containing plasmid (multiplicity of infection (MOI) of 
100) expressing a short hairpin RNA (shRNA) sequences and green fluorescence 
protein (GFP). Four specific constructs (seq A, seq B, seq C and seq D) were tested for 
efficiency compared to a negative control construct (Scr). Two weeks after infection, 
the percentage of GFP+ cells were measured by flow cytometry using the LSRFortessa 
cell analyser (Becton Dickinson) and GFP+ cells were then isolated using a FACS Aria 
cell sorter (Becton Dickinson). These cells were used for bone engraftment studies. 
 
3.4 Total RNA extraction, reverse transcription, and quantitative 
polymerase chain reaction (qPCR) 
 
Total RNA was extracted using the Quick RNA micro prep kit (Zymo Research) and 
subsequently quantified by NanoDrop 2000c Spectrophotometer (Thermo Scientific). 1 
µg of total RNA was reverse transcribed into cDNA using the High capacity Reverse 
Transcriptase kit (Applied Biosystems). 20 ng of cDNA were used and quantitative 
PCR was performed using the following Taqman Probes: Arg1 (Mm00475988_m1), tnf 
(Mm00443258_m1), Il23a (Mm00518984_m1), Tgfb1 (Mm01178820_m1), il6 
(Mm00446190_m1), Sparc (Mm00486332_m1), Ido1 (Mm00492586_m1), Cd40 
(Mm00441891_m1), Pd-l1 (Mm00452054_m1), Nos2 (Mm00440502_m1), Il-2 
(Mm00434256_m1), Socs2 (Mm00850544_g1), Mef2c (and beta-actin 
(Mm02619580_g1) and the Taqman Universal PCR Master Mix (Applied Biosystems). 
For human studies, the following Taqman probes were used: ZEB1 (Hs00232783_m1), 
ARG1 (Hs00163660_m1), PD-L1 (Hs00204257_m1), BETA-ACTIN 
(Hs03023943_g1). qPCR was performed on 7900HT Fast Real-Time PCR System 
(Applied Biosystems). Values were normalized to internal control (beta-actin) using the 
ΔCT method. 




3.5 In vivo murine models and bone marrow analysis 
Animal studies were approved by Institutional Committee for Animal Welfare and by 
the Italian Ministry of Health and performed in accordance with national law D.lgs 
26/2014 (authorization n. 781/2018-PR and 601/2019-PR). For our experiments, 10-15-
week-old female C57BL/6 mice were obtained from Charles River Italia (Calco, Italy). 
Tnfrsf5 (Cd40)-KO mice on a C57BL/6 (B6) background, were already available in our 
lab. For the experiments involving C1498 intra-bone (i.b.) injection, at day 0, 2x105 
Scr-C1498 or shZeb-1-C1498 cells were injected into the tibia of immunocompetent 
mice. After 34 days, mice were sacrificed, and bone marrow cells were collected from 
tibias by flushing to evaluate the AML cell engraftment, measured as frequency of 
GFP+ cells. BM samples were also stained to assess the immune landscape with flow 
cytometry analysis. For subcutaneous (s.c.) and intravenous (i.v.) injection, 1x106 Scr-
C1498 or shZeb-1-C1498 cells were injected in immunocompetent mice that were 
sacrificed after 30 days.  
Canonical bone marrow transplantation (BMT) experiments were performed using 
Lineage negative (Lin-) cells, that include all stem and progenitor cells negative for 
mature cell lineage markers (i.e. Mac-1 for myeloid cells, CD4 and CD8 for T-cells, 
CD19 or B220 for B-cells and Ter-119 for erythrocytes). 2 × 105 Lin- cells were 
transplanted from donors into lethally irradiated WT and Cd40-KO mice as previously 
described 206. Lin- cells were isolated from the BM of B6 mice using the Lineage Cell 
Depletion Kit (Miltenyi Biotec) according to manufacturer instructions.  
BM cells of mice injected with leukemic cells were stained with the following anti-
mouse monoclonal antibodies: PE conjugated anti-PD-L1 (clone), BB700 conjugated 
anti-CD11b (clone M1/70), APC conjugated anti-B220 (clone RA36B2), BV421 
conjugated anti-Ly6G (clone 1A8), BV605 conjugated anti-Ly6C (clone AL-21), 
BV786 conjugated anti-CD3 (clone 14S-2C11), PE conjugated anti-CD4 (clone 
GK1.5), APC conjugated anti-OX40 (clone OX-86), APC-Cy7 conjugated anti-CD8 
(clone 53-6.7), BV421 conjugated anti-PD1 (clone RMP1-30), BV421 conjugated anti-
TIM3 (clone SD12/TIM3) and BV650 conjugated anti-CD25 (clone PC61). For the 
intracellular staining, the Foxp3/Transcription Factor Staining Buffer Kit (Tonbo 
Biosciences) was used. Briefly, after surface marker staining, cells were washed with 
FACS buffer (PBS 1 X, 0,5 % EDTA, 3 % FBS) and fixed and permeabilized for 30 
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minutes using Foxp3 / Transcription Factor Fix/Perm buffer provided by the kit. The 
following antibodies were used: PerCp-Cy5.5 conjugated anti-Foxp3 (clone FJK-16S), 
FITC conjugated anti-IL17A (clone TC11-18H10), Alexa 647 conjugated anti-Ki-67 
(B56), BV510 conjugated anti-TNFα (clone MP6-XT22) and PE-CF594 conjugated 
anti-IFNγ (clone XMG1.2). All antibodies were purchased from Becton Dickinson.  
Samples were analysed with the FACSCelesta flow cytometer equipped with 
FACSDiva software (v 6.0) (Becton Dickinson). Flow cytometry data analyses were 
performed using FlowJo software (v10.2). 
 
3.6 Immunohistochemistry (IHC)  
For IHC analysis on humans, BM biopsies from 36 AML patients were used. No 
clinical informations concerning disease features and patients outcome are currently 
available.  
For IHC, Human and Murine BM samples were fixed in 10% buffered formalin, 
decalcified using an EDTA-based buffer, and paraffin-embedded. 4 µm-tissue sections 
were deparaffinized and rehydrated. Novocastra Epitope Retrieval Solution (pH 9) was 
used to unmask antigens in a PT Link Dako pre-treatment module at 98°C for 30 min. 
Subsequently, the sections were brought to room temperature and washed in PBS. After  
neutralization of the endogenous peroxidases with 3% H2O2 and Fc-blocking by a 
specific protein block, samples were incubated overnight at 4°C with primary 
antibodies: anti-mouse and human Zeb-1 (Novus Biological – 1:100), anti-human IL-17 
(1:100 dilution, Santa Cruz Biotechnology, Santa Cruz, CA), anti-human PD-1 (1:50, 
Biocare), anti-human HLA-DR anti-human CD3 (1:400, Dako), anti-human 
Osteonectin/Sparc, (1:500, Life technologies) and anti-human CD40 (abcam – 1:100).  
The immunostaining was revealed by either a polymer detection method (Novolink 
Polymer Detection Systems Novocastra Leica Biosystems Newcastle Ltd Product No: 
RE7280-K) and following specific secondary antibodies: horseradish peroxidase 
(HRP)-conjugated donkey anti-rabbit IgG (H+L) (A16035, Invitrogen) and 3,3’-
diaminobenzidine (DAB) substrate-chromogens.		
For immunofluorescence analysis on BM derived from C1498-Scr and C1498 silenced 
injected mice, samples were included in OCT. 8 µm cryostat sections from the frozen 
tissue samples were fixed with cold acetone for 10 min and then washed with PBS1X. 
Samples were blocked using a 10%FBS solution for 1h and stained using Alexa Fluor 
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488 Rat Anti-Mouse CD146 (Clone ME-9F1) and PE Rat Anti-Mouse CD40 (Clone 
3/23) for 2hs. Sections were washed, stained with DAPI for 5 min and then mounted 
using ProLong Gold Antifade Mountant (Thermo Scientific).  
 
3.7 Metastases quantification 
 
Livers from i.b. injected mice either with Zeb-1 expressing or silenced C1498 were 
explanted after 34 days, washed in PBS and fixed in 10% neutral buffered formalin 
overnight. Fixed samples were then embedded in paraffin. Four-micrometers-thick 
tissue sections were deparaffinized using xylol and firstly rehydrated in 100% ethanol 
for 5 min. Then, sections were incubated in 95%, 80%, 50% ethanol for 5 min and 
finally washed in distillated water. Sections were incubated with hematoxylin for 8 min 
and then washed. Eosin was added to the tissue sections for 3 min and then washed. The 
stained sections were dehydrated in 70% ethanol for 2 min, 100% ethanol for 2 min and 
finally in xylol twice for 5 min. Sections were mounted using Eukitt (Biosigma). 




30 µg of the total protein was separated on 8 or 12 % SDS–polyacrylamide gel 
electrophoresis under reducing conditions and transferred onto nitrocellulose 
membranes (Amersham, Biosciences). Following blocking with 5 % bovine serum 
albumin (BSA) and 0.1 % Tween-20, the membranes were incubated with the following 
antibodies: Polyclonal Anti-ZEB-1 antibody (NBP1-05987-Novus Biologicals – 
1:1000), and β-Actin (Cell Signaling– 1:1000) overnight at 4°C.  
After rinsing in tris-buffered saline (TBS) 0.1 % Tween-20, membranes were incubated 
with horseradish peroxidase conjugated goat anti-rabbit secondary antibodies (Thermo 
Scientific; 1:2000) and reactions were visualized with the Pierce ECL Plus Western 
Blotting Substrate (Thermo Scientific). 
 
3.9 Invasion assay 
2.5x105 C1498 cells either silenced or expressing Zeb-1 were resuspended in 200 µL of 
serum-free high glucose DMEM and placed onto the upper chamber of a 24-well 
transwell plate (5-µm pore size) coated with growth factor reduced matrigel (1 mg/mL). 
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750 µL of high glucose DMEM containing 10 % FBS was added into the lower 
transwell chamber. After 24 h at 37°C and 5% CO2, top chambers, containing non-
migrated cells were removed, while cells that migrated into the lower chamber were 
counted using the all-in-one digital inverted fluorescence microscope (EVOS fl – 
advance microscopy group). 5 randomly selected fields per well were counted. 
 
3.10 Proliferation assay 
To assess the proliferation of Zeb-1 expressing or silenced cells, we used the 
colorimetric Xtt assay. This test is based on the cleavage of tetrazolium salts added to 
the culture medium and allow the evaluation of cell viability and proliferation. Briefly, 
104 cells were seeded in a 96-well plate in 100 µl of DMEM 10% FBS for four different 
time point, termed t0, t24, t48 and t72. For each time point, plated cells were incubated 
with 50 µl XTT labelling mixture per well and incubate for 4 h at 37°C and 5 % CO2. 
Absorbance of the formazan products was measured at 450 nm Tecan's Spark 
Mircoplate reader, while the reference wavelength was read at 670 nm.  
 
3.11 In vitro suppression assay  
4 ×105 naïve C57Bl/6 splenocytes have been labeled with CFSE (Carboxyfluorescein 
Succinimidyl ester; 10mM, SIGMA Aldrich) and co-cultured with irradiated (3Gy) 
C1498 expressing or Zeb-1 silenced cells at different ratio in presence of 2 µg/ml of 
soluble anti-CD3 and 1 µg/ml of anti-CD28 to activate lymphocytes. Each sample was 
seeded in triplicate. Proliferation of CD4 and CD8 T cells has been assessed after 48h 
by flow cytometry evaluating CFSE dilution in the CD4+ and CD8+ gated populations.  
 
 
3.12 MDSCs and neutrophil isolation from human and mice 
G-MDSCs and anti-tumor neutrophils (N1) share common surface markers (CD11b, 
Ly-6G) but differently suppress T cell proliferation. MDSC subsets (CD11b, Ly-6G+ 
G-MDSC and CD11b, Ly6C+ M-MDSC) were isolated from mice bearing SN25ASP 
mammary tumors using the Myeloid-Derived Suppressor Cell Isolation Kit, mouse 
(Miltenyi Biotec) performing a magnetic beads separation. Anti-tumor N1-neutrophils 
were isolated from agar plugs as previously described by Sangaletti S et al 206. Briefly, 
neutrophils were collected from blocks of 2% agarose and 0.2% gelatin in saline 
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subcutaneously implanted in immunocompetent BALB/c mice. 5 days after the 
injection, agar blocks were explanted and washed 3 times with IMDM supplemented 
with 10% of FCS (GIBCO, Life Technologies). A total of 70%-75% of these cells are 
neutrophils that are enriched up to the 95% after 30 minutes of adherence on plastics. 
Regarding MDSC and neutrophil isolated from human samples, either from lung cancer 
patients and healthy donors, whole blood samples were diluted 1:4 with PBS 1X and 
subsequently subjected to a density gradient stratification. Briefly, diluted whole blood 
samples were carefully layered onto Ficoll-Paque PLUS (GE Healthcare) and 
centrifuged at 1800 rpm for 20 minutes at room temperature without brake. For MDSC, 
the lymphocyte-enriched ring at the interface was transferred into a new collection tube 
and washed with PBS 1X by centrifugation at 1500 rpm for 5 minutes. Samples were 
stained using the following antibodies: Lin1 (FITC); HLA-DR (APC eFl780), CD11b 
(BB700) and CD33 (PE). Total MDSC were sorted according to HLA-DR, CD33 and 
CD11b expression using a FACSAria BD Instrument. Regarding neutrophils, we 
isolated normal density neutrophils (ND) from the bottom layer generated after Ficoll 
stratification. Bottom layers from human samples were lysed using a 0.15M NH4Cl, 
10mM KHCO3 and 0.1mM EDTA solution. The 90% of cells are represented by 
neutrophils.  
 
3.13 Transient silencing of human neutrophils 
 
To achieve transient knock-down of ZEB-1 in human neutrophils, cells were transfected 
using a reverse transfection protocol in which siRNAs (Stealth siRNAs MSS210695, 
MSS210696, MSS210697, Thermo Fisher Scientific) and RNAiMAX (Thermo Fisher 
Scientific) have been used. A mix containing 3.25 µl of RNAiMAX in 200 µl Optimem 
(Gibco) and another one with 3.25 µl of siRNA (20 µM) stock were prepared, and after 
5 min at RT were combined and incubated at RT for 30-40 min. 4.5 x 105 neutrophils 
were seeded and after the incubation, the siRNA/RNAiMAX mix was added. Cells were 
incubated for 48 h and ZEB-1 knock-down and the modulation of selected 
immunosuppressive genes were assessed using qPCR.  
 
 




Murine BM-MSC cultures were obtained from the trabecular fraction of femurs and 
tibias of WT and CD40-KO mice. Briefly, the cellular fraction of the femurs and tibias 
was washed out and the compact bone was incubated with collagenase I (1 mg/ml) for 1 
h at 37°C. After enzyme digestion, the bone suspension was passed through a 70-mm 
filter mesh to remove any bone spicules and large tissues. Cells were seeded in 
complete medium at a density of 25 × 106 cells/ml. Floating cells were removed every 
3-4 days. Adherent cells were phenotypically characterized for the expression of the 
following markers: CD31, CD45, CD34, Ter119, CD44, Sca, and c-Kit. In vitro and in 
vivo experiments involving murine BM-MSCs were performed using cells between the 
2nd and 5th passages.  
 
3.15 Isolation	of	murine	BM-MSCs	from	lethally	irradiated	mice	
WT and CD40-KO 8-weeks-old mice were lethally irradiated (5 Gy) for 4 or 7 days. 
Then, MSCs were isolated as previously described in 3.14 by immunomagnetic 
separation using MACS Columns (Miltenyi) and recovered cells were lysed in RNA 
lysis buffer (Zymo Research). MSCs isolated from WT and CD40-KO mice were used 
as control.  
 
 
3.16 MSC stimulation and treatment with anti-CD40 monoclonal 
antibody  
 
To evaluate Cd40 modulation upon cytokine stimulation, MSCs isolated from wt or 
Cd40-KO mice were treated for 24h, 4 days or 7 days with IFN-γ (10 ng/ml), TNF-α 
(50 ng/ml), IL-1β (10 ng/ml), GMCSF (40 ng/ml), IL-6 (40 ng/ml), IL-17 (100 ng/ml) 
and TGF-β (5 ng/ml). To evaluate Ox40l expression upon cytokine stimulation, MSCs 
isolated from WT or Cd40-KO mice were treated with IFN-γ (10 ng/ml) and TNF-α (50 
ng/ml). For the experiment using agonistic CD40 monoclonal antibody, MSCs or DCs 
isolated from wt mice were stimulated for 2h with IFN-γ (10 ng/ml) and TNF-α (50 
ng/ml) and then treated for 24h with anti-mouse CD40 (Clone: FGK45.2) monoclonal 
antibody or isotype control (5µg/ml). All the cytokines were obtained from Peprotech. 
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3.17 Statistical analysis 
Differences between groups were assessed using student’s t-test or one-way analysis of 
variance (ANOVA), followed by Tukey’s post-hoc test. Data analyses were performed 
using GraphPad Prism software (version 6.0). Differences were considered statistically 
significant at p <0.05. In vivo experiments were performed in duplicate. In vitro 






4.1 Role of ZEB1 in stroma- and clone-related mechanisms of 
immunosuppression and aggressiveness in acute myeloid leukemia 
(AML). 
 
4.1.1 Zeb-1 is expressed by human MDSC and neutrophils and correlates with 
immunosuppressive markers 
 
In my hosting lab it has been previously shown that human immature myeloid derived 
suppressor cells (eMDSC) express the EMT-related protein SPARC. In these cells 
SPARC exerts immune suppressive activities acting on NF-kB signalling pathway 207. 
Extending the analysis to other EMT markers, we were able to show that murine MDSC 
along with mature neutrophils isolated from breast tumor bearing mice expressed Zeb-1 
(Figure 12A). Notably, MDSCs isolated from tumor bearing mice expressed higher 
levels of Zeb-1 than anti-tumor N1 neutrophils derived from agar plugs (Figure 12A). 
Moreover, we observed and enhanced expression of ZEB-1 levels in the MDSC or 
neutrophils isolated from lung cancer patients compared with those derived from heavy 
smoker volunteers (HS) (Figure 12B). Interestingly, ZEB-1 levels correlated with the 
expression of important immune-related genes, such PD-L1 and ARG-1 (Figure 12C), 
suggesting that neutrophils isolated from lung cancer patients can acquire a pro-tumoral 
phenotype, resembling MDSC functions. To evaluate the potential role of ZEB-1 in 
neutrophils, CD15+CD11b+CD66b+ cells were sorted from PBMCs of lung cancer 
patients and transiently knock-down for ZEB-1 expression using three specific siRNA 
sequences. Among the three sequences, only one was able to downregulate ZEB-1 
expression in human neutrophils as shown in Figure 12. Moreover, qPCR analysis 
showed that the reduction in ZEB-1 expression in interfered cells was associated with a 
reduced expression of the immune suppressive markers PD-L1, ARGINASE-I and TGFβ 
(Figure 12D). 
Immature MDSC phenocopy myeloblasts thanks to their clear immature morphology 
representing de facto the “normal counterpart” of leukemia blasts.  
The observation that ZEB-1 decreased is associated with reduced levels of immune 




cells, ZEB-1 could be both a marker of tumour aggressiveness but also an immune 
regulatory mediator helping leukemia cells in molding its associated immune 
suppressive milieu.  
 





































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 



















































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 


























































































































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 
















































































































































































































































































































A.  Q-PCR analysis showing Zeb1 xpr ssion in correlation with Pdl1 nd Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 




























































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 





























































































































































































































































































































































































A.  Q-PCR analysis sh wing Zeb1 expression i  correlation with Pdl1 and Il17 in murine G-a d M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 


























































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 



























































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 














































































































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M- DSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and M-MSC. C. The transient silencing of Zeb1 expression in 
DSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 















































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 



























































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 b t not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 



























































































































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 






































































































































































































































































































A.  Q-PCR analysis showing Zeb1 xpre sion in correlation with Pdl1 and Il17 in murin  G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 



















































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 


























































































































































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient sil ncing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3). E. Expression of ZEB1 in different population isolated from the PB of a metastatic 

























































































































































































































































































A.  Q-PCR analysis showing Zeb1 expression in correlation with Pdl1 and Il17 in murine G-and M-MDSC but not 
in N1-neutrophils B. IHC for ZEB1 in myeloid cells and BM-MSC. C. The transient silencing of Zeb1 expression in 
MDSC was performed with 3 different siRNA sequences. The sequence 2 was the most effective in decreasing 
Zeb1 level D. Down-modulation of Stat3 expression in MDSC transfected with the sequence 2 but not with 
scramble (or the seq1 and 3)  E. Expression of ZEB  in different population isolated from the PB of a metastatic 
breast cancer patient. 
Figure 12 – ZEB-1 expression is correlated with immune-modulatory marker levels in 
human MDSCs and PMN – A. ZEB-1 expression levels in FACS sorted neutrophils and 
MDSC (n=3) (Granulocytic (G)-MDSC and Monocytic (M)-MDSC subsets) isolated from 
tumor bearing mice. B. ZEB-1 expression levels in FACS sorted neutrophils 
(CD66b+CD11b+CD15+CD10+ normal density (ND) and eMDSC (n=3) (CD11b+ CD33high) 
isolated from healthy volunteers (heavy smokers – HS; n=5 for neutrophils and n=3 for 
eMDSC) and Lung Cancer (LC) patients (; n=5 for neutrophils and n=3 for eMDSC). C. PD-L1 
and ARG-1 expression levels in FACS sorted neutrophils (CD66b+CD11b+CD15+CD10+ 
normal density (ND) and eMDSC (CD11b+ CD33high) isolated from healthy volunteers (heavy 
smokers – HS; n=3) and Lung Cancer (LC; n=3) patients. D. ZEB-1 silencing is associated with 




4.1.2 Zeb-1 high levels identify a subgroup of Cytogenetically normal (CN)-AML 
patients with peculiar immune regulatory features. 
 
Considering the above hypothesis, we established an ad hoc collaboration with 
Dr.Curti/Dr. Simonetti from the University of Bologna, and performed a GEP analysis 
on a cohort of 61 AML patients’ BM samples (>= 80% blasts) and 7 healthy controls 
(HC) showing that ZEB-1 subdivided AML patients in two groups according to ZEB-1 
expression. We defined “ZEB-1low” (86,9% (53/61)) those patients who displayed ZEB-
1 expression levels below the average of HC and “ZEB-1high” (13.1% (8/61)) those 
patients expressing higher levels of ZEB-1 than the average of HC (Figure 13A). We 
analyzed karyotypic features of ZEB-1low and ZEB-1high AML and showed significant 
differences between them (p=0.0394, Monte Carlo simulated Fisher's exact test). In 
particular, ZEB1high AML associated with a normal karyotype (67% of ZEB-1high vs 
36% of ZEB-1low cases, Figure 13B). We therefore extended the analysis to public 
datasets from the Cancer Genome Atlas (TCGA) 204 and Beat AML 203. For in silico 
data, to define ZEB-1high and ZEB-1low AML, we used the median value of ZEB-1 
expression among patients. We observed that ZEB-1high and ZEB-1low patients showed 
differences in term of FAB classification (Monte Carlo simulated Fisher's exact test, 
p<0.0001); indeed, Zeb-1high patients were enriched in the undifferentiated M0 (18% vs 
3%) and poorly differentiated M1 (29% vs 17%) subtypes, while Zeb-1low were largely 
represented by M4 (27% vs 20%) and M5/7 (32% vs 7%) (Figure 13C). Moreover, in 
the same public available datasets, we assessed the association between ZEB-1 and the 
mutational profile, and we found significant differences in the combination of FLT3-
ITD and NPM1 mutations (p=0.005). In particular, ZEB-1high patients were enriched for 
FLT3-ITD/NPM1-mutant cases (16% vs 6%; p=0.0407) (Figure 13C). 
Focusing on our cohort (NGS-PTL), analysing the genes differentially expressed 
between ZEB-1high and ZEB-1low patients of our cohort, we found that, among the 
others, ZEB-1high patients were also characterized by a higher expression of SPARC 
(857.189 vs 311.137; p=0.015), PD-L1 (CD274) (27.144 vs 19.415; p<0.001) and CD40 
(28.045 vs 22.527; p=0.045) compared to ZEB-1low AML (Figure 13D). 
To test the clinical relevance of Zeb-1 as a prognostic biomarker, we evaluated whether 
ZEB-1 expression in AML patients can influence patients’ overall survival. To address 





Notably, in 2 independent cohorts (GSE37642 and GSE6891) we found differences in 






















































































p< 0.001 p= 0.045
ZEB1 low St Dev ZEB1 high St Dev P value
SPARC 311.137 419.660 857.189 1202.936 0.015
CD274 19.415 3.241 27.144 13.378 0.000
CD40 22.527 4.455 28.045 16.616 0.045
Bone marrow samples from 61 AML cases (>= 80% blasts)
Total bone marrow from healthy controls (n=7)
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Cytogenetic group ZEB1 low (% cases) ZEB1 high (% cases)
<3 alterations 32.3 6.7
Core binding factors 12.9 3.3
MLL or EVI1-
rearranged 3.2 10.0
Complex Karyotype 16.1 13.3





Figure 13 - ZEB-1 high levels identify a specific group of AML patients. A. ZEB-1 
expression levels obtained by GEP analysis in primary AML samples (n=61) and healthy 
controls (HCs, n=7; in green). The blue line indicates the mean value of normal controls that 
was used to discriminate ZEB-1high (n=8; in red) and ZEB-1low (n=53; in grey) patients. B. 




between the karyotypic features of ZEB-1high and ZEB-1low AML cases. C. Transcriptomic 
profile of AML samples from public datasets showed differences in term of FAB classification 
between ZEB-1high and ZEB-1low patients, being ZEB-1high patients enriched in the 
undifferentiated and poorly differentiated subtypes (M0 and M1). Evaluating the differences in 
term of mutations using the same datasets, we also found that ZEB-1high patients are associated 
with FLT3-ITD mutant cases. D. ZEB-1high AML patients were characterized by the higher 
expression of immune-regulatory molecules and EMT-related genes including PD-L1, SPARC 
and CD40 compared to ZEB1low AML. E. Kaplan-Meier curves showing that AML patients 
expressing high levels of ZEB-1 were associated with a poor prognosis and with a reduced 
overall survival after receiving conventional treatments compared with Zeb-1low patients (Log-




4.1.3 In situ expression of Zeb1 and its correlation with immune regulatory 
markers in human AMLs 
 
To investigate the expression of ZEB-1 at protein level we performed an 
immunohistochemical (IHC) analysis on 36 archival BM biopsies from AML patients, 
which were obtained from the University of Palermo (Dr. Tripodo Claudio) or the 
IRCCS Ospedale San Raffaele (Dr. Maurilio Ponzoni & Prof. Fabio Ciceri). We found 
that ZEB-1 was variably expressed in AML patients ranging from 5% up to 90% of 
blasts (Figure 14A).  
In these patients ZEB-1 showed a positive correlation with the expression of PD-L1 and 
IL-17. AML cases with slight ZEB-1 expression were almost completely devoid of PD-
L1 and showed a lower expression of IL-17. Notably, we found that Zeb-1high cases 
showed increased IL-17A expression if compared to Zeb-1low cases (Figure 14A). 
Double marker IF analysis showing a co-localization between IL17 and CD3 indicates 
that ZEB-1+ AML could be enriched in Th17 cells, that can sustain AML progression 

















































































Figure 14 – Zeb-1 levels in human AMLs is associated with the expression of immune 
regulatory markers – A. IHC analysis performed on archival BM biopsy (n=36) showed that 
in AML in which Zeb-1 is significantly expressed by the leukemic blasts, a parallel increased 
expression of PD-L1 and IL-17A was observed. B. IHC analysis performed on archival BM 
biopsy stratified according to Zeb-1 expression levels revealed that Zeb-1high patients were 




4.1.4 Zeb-1 expression in murine model of AML and its association with immune 
markers 
 
To model ZEB1+ AML we first evaluated ZEB-1 expression in available and 
transplantable murine models of AML: the C1498 cells, syngeneic in C57BL/6 mice 
and the WEHI-3B cells, syngeneic in BALB/c mice. As positive control for Zeb-1 
protein levels we used BM-MSCs. Western blot analysis and qPCR showed that C1498 
cells display high levels of Zeb-1 compared with WEHI-3B that were almost negative 
for Zeb-1 expression (Figure 15A).  
Interestingly, the different expression of Zeb-1 in C1498 and WEHI-3B cell lines was 
associated to a different expression of immune related molecules.   
We observed higher levels of Pd-l1, Arg-1, Il-2 and Tgf-β in Zeb-1+C1498 AML cells 
compared with Zeb-1neg-WEHI-3B, confirming the results obtained by GEP analysis 
and IHC. On the contrary, WEHI-3B expressed a different pattern of immune-
regulatory genes, that included Nos2, Il-6, Il-23 and Ido-1 (Figure 15B), suggesting that 
either Zeb-1high or Zeb-1low leukemic cells may be able to promote immunosuppression 





















































































































































































Figure 15 – C1498 murine AML cell line express high levels of Zeb-1 – A. Western blot 
analysis and qPCR showed the expression of Zeb-1 in WEHI-3B and C1498 murine AML cell 
lines either at protein or mRNA levels. BM-derived mesenchymal stem cells (MSC) isolated 
from BALB/c (B/c) mice were used as Zeb-1 positive control. β-actin was used as internal 
control. B. qPCR showed that C1498 and WEHI-3B cell lines were characterized by the 
expression of a peculiar pattern of immune-regulatory genes. Results are expressed as mean ± 




4.1.5 Zeb-1 silencing impairs cell-intrinsic immunosuppressive properties of AML 
blasts 
 
To study the interaction between ZEB-1+AML and the immune microenvironment we 
used a lentiviral vector-based approach to silence ZEB1 expression in C1498 cells 
(Figure 16A). To this end we used four target-specific shRNA (seq A, seq B, seq C and 
seq D) and a negative control (scramble control). The presence of the GFP tag, allowed 
the selection of GFP positive cells through FACS sorting. We obtained four different 
silenced cells that were called C1498 Zeb-A (C1498 shZeb A), Zeb-B (C1498 shZeb 
B), Zeb-C (C1498 shZeb C) and Zeb-D (C1498 shZeb D) and a negative control 
“C1498-Scr”. We found that all target-specific shRNA decreased Zeb-1 expression, 
both at RNA and protein levels compared with the negative control (scramble control) 
even if displaying a different efficiency (Figure 16B, C).  
We first assessed whether Zeb-1 downregulation affected the immunosuppressive 
repertoire of C1498 cells. To perform this analysis and in vivo experiments we selected 
the two clones showing the best efficiency in ZEB-1 silencing. Comparing the two 
selected clones (ZEB-C and ZEB-D) with the control (C1498–Scr), we observed that 
Zeb-1 downregulation decreased the expression of Il-6, Tgfβ, and Arginase-1 (Arg1) but 
increased the expression of Il-2 levels (Figure 16D). Notably, the last represent a sort of 
positive control as ZEB-1 was initially discovered as IL2 negative regulator 208. 
Somewhat surprisingly, in the C1498 model, no alterations in Pd-l1 expression were 
observed comparing the Scr and the silenced cells (Figure 16E) and, of note, only seqC 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 16 – Zeb-1 knock-down using lentiviral particles in C1498 – A. C1498 were infected 
using different lentiviral particles containing plasmid expressing a short hairpin RNA (shRNA) 
sequence and green fluorescence protein (GFP). Four specific constructs (seqA, seqB, seqC and 
seqD) were tested for efficiency compared to a negative control construct (Scr). Flow cytometry 
was used to evaluate the percentage of infection and GFP+ cells were FACS sorted. B. qPCR 




silenced cells. β-actin was used as internal control. Results are expressed as mean ± SEM (**p< 
0.01). D. qPCR showed that silenced cells expressed altered levels of crucial immune regulatory 
genes including Arg-1, Tgfb, Il-6 and Il-2 E. no changes in the expression levels of Pd-l1 were 
observed in the silenced cells compared with Scr. F. Sparc expression was reduced only in seqC 
silenced cells, while no alterations in its expression were observed in shZeb-1 seq D cells. 
Results are expressed as mean ± SD of at least three independent experiments (*p< 0.05; **p< 
0.01; ***p<0.001; ****p<0.0001) 
 
 
4.1.6. C1498 cells suppress T-cell proliferation via ZEB-1 
 
The strong modulation of Arg-1 and Il-2 expression upon Zeb-1 silencing, two key 
molecules able to negatively or positively interfere with T cell activation, respectively, 
suggested to evaluate whether the similarities between AML cells and MDSCs were 
rather than morphological also functional. We therefore evaluated whether C1498 AML 
cells were able to directly suppress T cell proliferation and if ZEB-1 silencing was able 
to interfere with this activity.  
To perform this experiment C1498 cells were irradiated, to block their proliferation, and 
co-cultured with αCD3-αCD28 stimulated CFSE-labelled T-cells (total splenocytes) at 
different ratio. Proliferation was assessed 48h after. C1498 cells efficiently suppress 
proliferation of T-cells if compared with ZEB-D silenced cells in particular at higher 
doses of C1498 cells, which represents a more physiological condition as the 





















































































































































Figure 17 – Zeb-1 expression is associated with immunosuppressive abilities in C1498 - 
irradiated C1498 cells were co-cultured with αCD3-αCD28 stimulated CFSE-labelled T-cells 




Results are expressed as mean ± SD of at least two independent experiments (*p< 0.05; **p< 





4.1.7 Zeb-1 downregulation is associated with the decreased C1498 engraftment 
within the BM  
 
To evaluate the impact of stable ZEB-1 silencing on tumour immune microenvironment 
in vivo we set up a murine model in which Zeb-1 expressing C1498 (Scr) or silenced 
(ZEB-D) cells were injected in the tibias of syngeneic immunocompetent C57BL/6 
mice. 
Mice were sacrificed after 34 days from injection and, at first, we evaluated the 
differences in cell engraftment in term of GFP positive cells within the mice BM. 
We observed that the percentage of GFP+ leukemic cells was higher in the bone 
marrow of mice injected with Scr compared with silenced ZEB-D cells (Figure 18A), 
confirming that Zeb-1 expression in leukemic cells support and improve AML cell 
engraftment. To further confirm this finding, we use other two widely used route of 
administration. Thus, parental and silenced cells were also injected subcutaneously 
(s.c.) (Figure 18B) and intravenous (i.v) (Figure 18C) in immune competent mice. For 
subcutaneous tumors explanted from mice, we observed the formation of a fibrotic 
capsule around tumors. Given this, since the tumor dimensions cannot be considered 
informative due to the formation of fibrotic tissues, to better characterize the frequency 
of tumor cells, we assessed the percentage of GFP+ cells within the tumors, confirming 
the impaired ability of Zeb-1 silenced cells to growth in vivo. Indeed, only 3 out of 10 
mice injected subcutaneously with silenced cells were able to develop tumours and the 
percentage of GFP+ cells in explanted tumours were lower than in tumours derived 
from Scr injected mice. Accordingly, also the frequency of GFP+ leukemic cells was 
higher in mice injected i.v. with Scr cells compared with those injected with the shZeb-
1 counterpart, clearly demonstrating that the downregulation of Zeb-1 significantly 




































Figure 18 – Zeb-1 silencing impairs the engraftment abilities of C1498 – A. C1498-Scr 
(n=13) and shZeb-1 (n=12) were injected in the tibia of immunocompetent C57BL/6 mice and 
the percentage of GFP+ cells within the BM was evaluated with flow cytometry 34days post 
injection. Naïve mice were used as controls. Representative dot plots are shown B. C1498-Scr 
(n=10) and shZeb-1 (n=10) were injected subcutaneously in C57BL/6 mice. The percentage of 
mice engrafted with the two lines was shown and the frequency of GFP+ cells within the 
tumours was reported C. C1498-Scr (n=9) and shZeb-1 (n=8) were injected intravenous in 
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Figure 18 – Zeb-1 silencing impairs the engraftment abilities of C1498 – A. C1498-Scr 
(n=13) and shZeb-1 (n=12) were injected in the tibia of i munocompetent C57BL/6 mice and 
the percentage of GFP+ cells withi  the BM was evaluated with flow cytometry 34days post 
injection. Naïve mic  were used as controls. Representative dot plots are shown B. C1498-Scr 
(n=10) and shZeb-1 (n=10) ere injected subcutaneously in C57BL/6 mice. The percentage of 
mice engrafted with the two lines was shown and the frequency of GFP+ cells within the 
tumours was reported C. C1498-Scr (n=9) and shZeb-1 (n=8) were injected intravenous in 
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Figure 18 – Zeb-1 silencing impairs the engraftment abilities of C1498 – A. C1498-Scr 
(n=13) and shZeb-1 (n=12) were injected in the tibia of immunocompetent C57BL/6 mice and 
the percentage of GFP+ cells within the BM was evaluated with flow cytometry 34 days post 
injection. Naïve mice were used as controls. Representative dot plots showing the percentage of 
GFP within the BM of injected mice are shown B. C1498-Scr (n=10) and shZeb-1 (n=10) were 
injected subcutaneously in C57BL/6 mice. 31 days after injection, the percentage of mice 
engrafted with the two lines was shown and the frequency of GFP+ cells within the tumours 









4.1.8 Decreased AML engraftment in mice injected intra-bone with shZEB1 cells is 
associated with the expansion of cytotoxic CD8+ cells  
 
 We next evaluated the impact of ZEB-1 in instructing the BM immune 
microenvironment and its effect on specific BM immune populations. To this end we 
performed a multiparameter flow cytometry analysis on BM of transplanted mice that 
allow the evaluation of many different immune populations in the same sample. FACS 
analysis shows an increase in CD3+ cell frequency, while no significant changes were 
observed on total CD11b+ cells (Figure 19A). However, within the CD11b gate, we 
found a lower frequency of Ly6GhighLy6Clow (G-MDSC) cells in shZeb-1 injected mice 
(Figure 19B). Moreover, no alterations were found in the percentage of B220+ B cells 
(Figure 19C).  The increase in CD3 frequency was associated with changes in 
CD4/CD8 ratio that was in favour of CD8 T cell in mice receiving ZEB-1 silenced cells. 
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Figure 19 – Zeb-1 expression in C1498 is able to shape the BM immune microenvironment 
– A. Frequencies of CD3+ and CD11b+ cells within the BM of control mice (CTRL B6, n=5) or 
mice injected with Zeb-1-expressing (Scr, n=13) or silenced cells (shZeb-1, n=12) 34days post 
injection. B. Frequencies of G-MDSC (Ly6GhighLy6Clow) and M-MDSC (Ly6ChighLy6Glow) cells 
within the gate of CD11b cells 34days post injection C. Frequencies of B220 lymphocytes and 
alterations of CD4/CD8 ratio and Teff/Treg ratio within the BM of injected mice (CTRL B6, 
n=5, Scr, n=13, shZeb-1, n=12) 34days post injection. Results are expressed as mean ± SD of 
two independent experiments ( *p< 0.05; **p< 0.01; ***p<0.001; ****p<0.0001). 










Focusing on CD8 T cell subpopulation. FACS analysis showed a higher frequency of 
IFNγ+ CD8 T cell infiltrating the BM of mice injected with the silenced (ZEB-D) clone. 
(Figure 20A). CD8 T cells were also more proliferating showing an increased 
frequency of Ki-67 staining. Moreover, we also observed an increase in CD8+ PD-1+ 
cells (Figure 20B). Since PD1 is expressed on activated CD8 T-cells but is also a 
marker of exhaustion to better characterize this subpopulation we assessed the 
expression of TIM3, another marker of exhaustion and evaluated the ability of 
CD8+PD1+ to produce IFNγ.  We found the increase of CD8+PD-1+Ki67+IFNγ+ cell 
fraction and the concomitant reduction of PD1+TIM3+ frequency (Figure 20C) in the 
BM of mice injected with the silenced cell line, confirming that Zeb-1 downregulation 
in leukemic cells is associated with the expansion of activated T cells. In addition, we 
observed an expansion of CD8+OX40+ lymphocytes (Figure 20D). OX40 triggering in 
Teff and CD8 T cells is associated both with the activation and cytokine production but 






















































































































































































































































Figure 20 – Zeb-1 down-regulation in C1498 is associated with the expansion of CD8 
activated T-cells – A. Frequencies of total and IFN-γ producing CD8+ within the BM of control 
mice (CTRL B6, n=5) or mice injected with Zeb-1-expressing (Scr, n=13) or silenced cells 
(shZeb-1, n=12) 34days post injection. A representative dot plot showing the frequency of 
IFNγ+ CD8+ cells is displayed B. Frequencies of proliferating CD8+Ki67+ and PD1 expressing 
CD8 lymphocytes 34days post injection C. Frequencies of exhausted (PD1+TIM3+) and 
activated (PD-1+Ki67+IFNγ+) CD8 lymphocytes 34days post injection D. Percentage of 
CD8+OX40+ lymphocytes within the BM of injected mice (CTRL B6, n=5, Scr, n=13, shZeb-
1, n=12) 34days post injection. Results are expressed as mean ± SD of two independent 







The strong activation of CD8 T cell in the BM of mice receiving ZEB1-silenced C1498 
cells, was further supported by qPCR analysis performed on total BM cells showing an 
overall increase in Ifn-γ, Perforin and Ox40l within the BM of ZEB-D injected mice 
compared to Scr (Figure 21).   
In line with this, a trend toward an increased production of cytotoxic factors, such as 
Granzyme B and Tnf was also observed with the concomitant decrease of 






































































































































































































Figure 21 – Zeb-1 down-regulation was associated with an increase of cytotoxic cytokine 
release and with the concomitant decrease of immunosuppressive factors within the BM – 
mRNA levels of selected cytokines produced within the BM of mice injected with C1498 
expressing or silenced for Zeb-1. BM of naïve mice was used as control. Beta-actin was used as 








The main findings showing that the downregulation of Zeb-1 in C1498 is associated 
with the T cell activation were also confirmed in the BM of mice injected i.v. (Figure 
22A) and in the tumours derived from mice injected subcutaneously (Figure 22B). In 
particular we observed an increased frequency of cytotoxic CD8+ cells producing type I 
cytokines such IFN-γ and TNF-α in the BM of mice injected with shZeb-1 cells along 
with the expansion of CD8+PD1+ cells compared to mice that receive Scr counterpart, 





















Figure 22 – Zeb-1 downregulation is associated with the expansion of activated CD8+ cells 
regardless the route of administration – A. Frequencies of CD8+ IFN-γ+, CD8+PD1+ 
proliferating and activated T-cells within the BM of mice injected i.v. with Zeb-1-expressing 
(Scr, n=10) or silenced cells (shZeb-1, n=8) 30days post injection. B. Frequencies of CD8+ 
TNF-α+, CD8+Ki67+ and CD8+Ki67+PD1+ cells in mice (Scr n=7; shZeb1 n=3) 30days post 







































































































































































4.1.9 Reduced expansion of IL17+ CD3 cells in the BM of mice receiving shZEB1 
C1498 cells 
 
Evaluating the CD4 population the BM of mice injected with shZEB1 C1498 cells 
showed an increased frequency of CD4+ cells producing IFN-γ and TNF (Figure 23A). 
Interestingly, in the same group of mice, we found decreased production of IL-17 by 
CD3+ cells and particularly by Treg cells (Figure 23B). IL17A+ Treg represents a 
particular subset of Treg that have been involved in the maintenance of the immune 
suppressive environment in cancer patients 209-212.  
The differentiation of Th17 cells relies on known factors including TGFβ, IL-6 and IL-
23. According to the reduction in IL-17+ cells, silenced cells showed a significant 














































































































































































































































































Figure 23 – Zeb-1 expression promote the expansion of CD4+IL-17+ suppressive cells – A. 
Frequency of activated CD4 lymphocytes producing IFN-γ and TNF type I cytokines and Teff 
TNFα+ cells within the BM of injected mice (CTRL B6, n=5, Scr, n=13, shZeb-1, n=12) 
34days post injection. Representative dot plots showing percentage of CD4+TNFα+ cells are 
shown B. Frequency of IL-17+ CD3+ cells, IL-17+ CD4+ cells and Treg cells producing IL-
17within the BM of injected mice (CTRL B6, n=5, Scr, n=13, shZeb-1, n=12) 34days post 




expression of Il-23 in expressing or Zeb-1 silenced cells. Results are expressed as mean± SD of 
two independent experiments, *p< 0.05; **p< 0.01. Representative dot plots are shown. 
 
4.1.10. IL17 promotes C1498 cells proliferation and the expression of stemness 
markers   
To evaluate the biological significance of IL-17 in our context, C1498 cells expressing 
or silenced for Zeb-1 were firstly investigated for Il17 receptor a (Il-17ra) expression by 
FACS. We did not observe any difference in term of frequency of cells expressing the 
selected marker as far as in term of intensity (mean fluorescence intensity – MFI)  
among silenced or Zeb-1 expressing cells (Figure 24A). Thus, we decided to treat 
C1498 cells for 24 h, 48h, 72 h, 4 days and 7 days with rIL-17. As a read out we 
evaluated cell proliferation and the expression of stemness markers. We found that 
rIL17 promoted C1498 cell proliferation (Figure 24B) and the expression of Socs2, 
Mef2c and Mmp9 (Figure 24C), two key factors involved in controlling proliferation 
and stemness of hematopoietic cells also defining unfavourable leukemia 213,214.  
Interestingly the treatment of C1498 cells with rIL-17 for 7 days induced the expression 
of Tgfβ and il-23 (Figure 24C), thus promoting a Th17 self-maintaining loop. No 
differences in Arg1 expression were observed. Overall, these data suggest that the 
induction of Th17 cells in the leukemia microenvironment by ZEB1 could sustain 
tumour aggressiveness through the induction of stemness factors that could be involved 
for example in mediating tumour relapse after chemotherapy. In line, a GEP analysis 
performed onto matched AML blasts obtained at diagnosis and at relapse showed the 
enrichment in ZEB1 expression in relapsed sample along with an enrichment in the 
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Figure 24 – IL-17A promote and sustain AML aggressiveness – A. FACS analysis showing 
IL-17RA levels among the Zeb-1 expressing or silenced cells. B. Cell proliferation was assessed 
by Xtt assay after 24h, 48h and 72h of IL17A stimulation 50 ng/mL. C. qPCR showing the 
induction of Socs2 and Mef2c and immune-regulatory markers upon stimulation (7 days) with 
IL17A 50 ng/mL D. ZEB- 1 expression levels at diagnosis and relapse. E. IL-17 enrichment 







4.1.11 Zeb-1 silencing impaired the invasive ability of C1498 without affecting cell 
proliferation 
 
To assess in vitro the invasive ability of Zeb-1 expressing or silenced C1498 we use a 
transwell-based assay. We demonstrated that all the sequences used to downregulate 
Zeb-1 reduced the invasion of C1498 compared to negative control (Figure 25A). This 
evidence was also confirmed in vivo.  
According to this experiment, in vivo we found a reduction of the liver metastatic areas 
in mice injected i.b. with shZeb-1 compared to Scr injected mice (Figure 25B). 
Moreover, we noticed diffuse and nodular infiltration in the liver parenchyma of Scr 
C1498-GFP injected mice, while in shZeb-1 C1498-GFP injected mice leukaemic cells 
were found mostly around blood vessels (Figure 25B), pointing out the limited invasive 
ability of silenced cells compared with controls. Molecularly, this phenomenon is 
associated with a significant reduction of Mmp9 expression in silenced cells compared 
to Scr-C1498 (Figure 25C). Finally, to assess whether Zeb-1 silencing could negatively 
impact on cell growth, we performed an XTT assay showing that Zeb-1 downregulation 































































































































Figure 25 – Zeb-1 expression is associated with an increased invasiveness in leukemic cells 
– A. In-vitro invasion assay using 24-well transwell plates (5 µm pore size) coated with 1 
mg/ml Matrigel® growth factor reduced basement membrane matrix. Five consecutive fields 
per tranwell were counted. Representative fields are shown B. Hematoxylin and eosin staining 
of liver explanted from Scr-injected and shZeb-1 injected mice. Metastases area quantification 




silenced cell lines (shZeb seq C and shZeb seq D); beta-actin was used as internal control D. 
XTT proliferation assay performed on Zeb-1 expressing (Scr) and silenced cell lines (shZeb seq 
C and shZeb seq D). Cell proliferation for each time point was calculated as the (Absorbance 
(Abs) at 450 nm – Abs at 670 nm) t24/48/72)/ (Abs at 450 nm – Abs at 670 nm) t0*100. Results are 
expressed as mean± SD of two independent experiments, **p< 0.01; ***p<0.001. 
 
 
4.1.12 Zeb-1 silencing influences the immune-modulatory properties of the stromal 
compartment 
So far, we demonstrated that Zeb-1 expression in leukemic cells skew the BM immune 
microenvironment toward Th17 differentiation to sustain AML development and 
progression. We next challenged whether leukemia cells could also influence the 
activity of BM-MSCs, which through the induction of soluble factors like IDO-1 and 
NOS2, are known to exert suppressive activity in the BM.  
To address this point, we decided to investigate the expression of key immune 
regulatory molecules on BM-MSCs from mice injected with silenced or Zeb-1 
expressing C1498.  
Given the relevance of CD40 expression in lymphoma patients221, we firstly verified 
whether MSCs from mice injected with leukemic cells were able to express Cd40. 
Therefore, we performed an immunofluorescence analysis showing the presence of 
double positive Cd146+ Cd40+ elements within the BM of injected mice (Figure 26A).  
Then, we evaluated the expression of key immune regulatory molecules, including Ido-
1, Cd40, Il-6 and Tgfb at mRNA levels isolating BM-MSC from mice injected with 
silenced or Zeb-1 expressing C1498 (Figure 26 B, D). We observed that BM-MSCs 
derived from mice injected with C1498-Scr cells up-regulated the expression of Cd40 
(Figure 26B) non only compared with naïve control mice, but, more importantly, 
compared with shZeb-1 C1498 injected animals.  
In addition, an increased expression of Il-6 (Figure 26C) and Ido-1 (Figure 26D) was 
found in BM-MSC isolated from mice injected with C1498-Scr compared with mice 
injected with silenced cells. Interestingly, no changes were observed in the Tgf-β 
expression (Figure 26C).  
The induction of Cd40 and Ido-1 in BM-MSC was further corroborated by IHC analysis 




injected with silenced cells if compared to mice injected with C1498-Scr, reduction that 
was particularly evident in BM-MSCs (Figure 26 B, D).  
Interestingly the treatment of ex-vivo isolated BM-MSCs with rIL17 induced an 
increase in Cd40 expression.  Notably, we also found the up-regulation of il-6 and il-1β 
(Figure 26 E) upon IL-17a stimulation, highlighting a possible positive feedback loop 
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Figure 26 – Zeb-1 downregulation impacts on immune-modulatory MSC abilities. A. 
immunofluorescence showing CD146+ (green) CD40+ (red) cells within the BM of C1498 
injected mice. B. qPCR showing Cd40 expression on BM-MSCs isolated from mice injected 
with Scr or shZeb1 cells and IHC confirming stromal Cd40 up-regulation in Scr injected mice. 
C.  qPCR showing Il-6 and Tgf-β expression on BM-MSCs isolated from mice injected with Scr 
or shZeb1 cells. D. qPCR showing Ido-1 expression on BM-MSCs isolated from mice injected 
with Scr or shZeb1 cells and IHC confirming stromal Ido-1 up-regulation in Scr injected mice. 
E. qPCR showing Cd40, Il-6 and Il-1β expression on ex-vivo IL-17A (50 ng/ml – 24h) 




4.1.13 CD40 is expressed by AML patient-derived MSCs  
 
It is now widely accepted that BM-MSCs can be endowed of immune-regulatory 
activities as reviewed by Nauta et al 112, by suppressing the release of inflammatory 
cytokines such as IFN-γ and IL-12 and concomitantly promoting the secretion of 
immunosuppressive IL-10 by dendritic cells 121 or regulating T-cell functions 215. 
Moreover, we have previously reported (1.9.1 chapter) that in particular pathological 
condition, such as during lymphomagenesis and progression, MSCs stromal cells that in 
physiological conditions express very low levels of CD40, are able to up-regulate its 
expression and sustain tumor growth 201. Thus, we hypothesized that also in AML 
patients CD40 expression on stromal cells can be relevant in shaping BM tolerance 
during leukemia cell growth. For this reason, we at first investigated the expression of 
CD40 on human MSCs following co-culture with AML patients’ leukemic cells. We 
observed that CD40 expression, along with other crucial markers, was variably induced 
in MSC cells by blasts, suggesting that, as occurred in lymphoma patients, the 
expression levels of CD40 can also be consistently different among AML patients 
(Figure 27A).  
To better study the expression of CD40 within the BM of AML patients, we used an 
independent cohort of 9 archival BM biopsy samples from the Tumor Immunology Unit 
of the University of Palermo. We observed that CD40 was induced on stromal cells of 
AML patients compared with the healthy subject. Moreover, as expected, we found 




















































































Figure 27 – CD40 is induced on MSCs after co-coture with blasts isolated from AML 
patients – A. qPCR showing the expression of Cd40, Pd-l1, Zeb-1 and Sparc selected markers 
upon the co-colture with AML patients derived blasts (n=8) and healthy donors (BM88 and 
BM82). Gapdh was used as internal control. B. IHC staining performed on 9 AML patients 
showed that only some patients expressed CD40 on mesenchymal elements. BM of healthy 
subject was used as negative control. Magnification: 20X 
 
 
4.1.14 CD40 stromal expression allow AML take and dissemination 
 
To assess the relevance of stromal Cd40 expression on AML development, we injected 
105 GFP-tagged C1498 cells i.v. in WT and Cd40-KO	mice. Following 30 days, mice 




liver was evaluated. We found that the engraftment of WT mice was higher compared 
with Cd40-KO mice and, notably, we also observed an increased percentage of GFP+ 





















Figure 28 – CD40 expression support AML engraftment and dissemination – Frequency of 
C1498-GFP+ cells in C57BL/6 mice (n=5) and Cd40-KO mice (n=5). Results are expressed as 





Overall, these data highlighted the relevance of CD40 in the BM microenvironment and 
in leukemia cell take.  To study and better appreciate the relevance of CD40 in 
regulating BM immune homeostasis we moved to an hematopoietic stem cell 














4.2 Stromal-derived CD40 regulates bone marrow immune 
homeostasis 
 
4.2.1 CD40 stromal expression is induced by pro-inflammatory cytokines 
 
In physiological conditions BM-MSCs do not express CD40, while we hypothesized 
that lethal radiation, that is the pre-transplantation regimen that resemble a stress 
condition, could be able to enhance CD40 expression on MSCs. To assess whether 
lethal radiation was able to induce CD40, we performed a qPCR on ex-vivo isolated and 
purified BM-MSCs showing an increased expression of CD40 at day 7 post-radiation 
compared to basal levels (Figure 29A). FACS analysis also showed the increase of 
CD40+ MSCs in both BALB/c and C57BL/6 lethally irradiated compared with non-
irradiated mice (Figure 29B). As expected, no differences were observed in Cd40-Ko 
mice that were used as a negative control (Figure 29B). Histological analysis and IHC 
showed a visible upregulation of CD40 expression in the stroma of irradiated mice 
comparing to control non-irradiated mice (Figure 29C). Upon radiation, we also 
showed the up-regulation of Il-2 expression levels, a cytokine required for Treg survival 
and proliferation, only in CD40 wt MSC (Figure 29D). Moreover, we observed an 
increase of other immunomodulatory molecules in CD45.1 MSC, including IDO, PD-
L1 and NOS2 while no changes have been found in Cd40-KO MSC (Figure 29E). 
These results clearly demonstrated the potential crucial role of CD40 in the promotion 
of the immune-suppressive environment and in particular, pointed out the potential 










































































































































































































































































































































FIGURE 2 | Expression of CD40 in the BM microenvironment. (A) Representative image of CD40 IHC staining in the femurs and tibias of WT mice harvested 7 days
post-irradiation. (B) FACS analysis showing the up-modulation of CD40 on BM-MSC isolated from irradiated (RAD) and non-irradiated (CTRL) BALB/c (CTRL n=5;
RAD n=4) and Cd40-KO mice (CTRL n=5; RAD n=2). *p < 0.05, Mann-Whitney test. (C) FACS analysis showing the up-modulation of CD40 on CD169+ cells
isolated from irradiated (RAD) and non-irradiated (CTRL) BALB/c (CTRL n=5; RAD n=4) and Cd40-KO mice (CTRL n=5; RAD n=2) *p < 0.05, Mann-Whitney test.
(D) RT-PCR analysis showing the expression of CD40 on primary BM-MSCs (not expanded in vitro) purified from BM at days 4 and 7 post-radiation and compared
to basal expression. *p < 0.05, Mann-Whitney test (n=5/group). (E) Cumulative FACS analysis showing the frequency of Sca-1+ and Sca-1- BM-MSCs
(CD29+CD44+CD45-Ter119-CD31-CD117-CD34- gate) in irradiated mice (**p < 0.005; Student t test; n=8 for controls and n=10 for irradiated mice). (F) Cumulative
FACS analysis showing the frequency of CD73+ and CD40+ BM-MSCs within the Sca-1+ and Sca-1- gate (n=8 for controls and n=10 for irradiated mice). *p <
0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001, Tukey’s multiple comparisons using a one-way ANOVA. (G) Cumulative FACS analysis showing the frequency of
CD40+CD73-, CD40+CD73+, and CD40-CD73+ BM-MSCs in irradiated (RAD) vs non-irradiated mice (CTRL). n=8 for controls and n=10 for irradiated mice; **p <
0.005, ***p < 0.001, ****p < 0.0001, Tukey’s multiple comparisons using a one-way ANOVA. (H) Triple marker confocal microscopy analysis showing CD146+
(green, panels above) or CD169+ (panels below) elements in B220+ (red) and CD43+ (blue) cells. Arrows in the two enlargements indicate the spatial localization of
B220+ (red arrow) and CD146+ (green arrow panel above) or CD169+ (green arrow panel below) cells. CD43+B220+ double positive cells (asterisk) are B cell
precursors. The analysis indicated that B220+ (in part CD43+) exhibits preferential contact with CD146 but not CD169+ cells.
Bassani et al. Stromal CD40 Regulates T-Cell Homeostasis
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Figure 29 – CD40 was up-regulated on BM-MSCs upon lethal radiation and its expression 
was associated with the increase of immuno-modulatory molecules – A. qPCR showing the 
increase of Cd40 expression 4 and 7 days post radiation B. FACS analysis showing the up-
modulation of CD40 on BM-MSC isolated from irradiated (RAD) and non-irradiated (CTRL) 




n=6; RAD n=2) C. IHC showing the increase of CD40 on stromal elements within the BM of 
irradiated mice compared with controls D. qPCR showing the increase of il-2 expression in 
C57BL/6 (CD45.1) irradiated mice (n=3)  E. up-regulation of Pd-l1, Ido-1 and Nos2 expression 




Since we assumed that the acquisition of CD40 by stromal BM-MSCs is able to 
influence their ability to promote immunosuppression, we then analysed the alterations 
within the BM microenvironment occurred in irradiated mice, focusing on the 
radioresistant T-cells, including both Teffs and Tregs. Indeed, for our hypothesis, it is 
expected that T cells can be influenced by soluble factors released by MSCs. However, 
we speculated that some cytokines, such as IFNg and TNFa produced by T-cells can 
modulate the expression of CD40 on MSCs in turn regulating their immune-regulatory 
properties.  
Compared to the controls, the lethally irradiated mice showed an overall increased 
frequency of CD4+ T-cells, whereas the number of CD8+ T-cells was not significantly 
different (Figure 30A). Among the CD4+ T-cells, we observed an increased percentage 
of Teffs and the concomitant decreased frequency of Tregs (Figure 30B). Moreover, we 
also found that Teffs were activated and released TNF and IFN-γ,  two cytokines that 
have been reported to regulate the immune-modulatory properties of MSCs 113 (Figure 
30C). 
Thus, we performed in vitro studies evaluating the potential ability of these cytokines to 
induce CD40 on BM-MSC (Figure 30D) and we found that TNF and IFN-γ were able 
to up-regulate cd40 expression, while no effects were exerted by other stimuli that were 
also released in the conditioned BM (i.e., G-CSF, GM-CSF+IL-6, and IL-17) or are 
conventionally used to stimulate mesenchymal cells (i.e., TGFβ) (Figure 30D). 
Notably, to test whether the gain of immune regulatory features in BM-MSCs occurred 
at the expense of their differentiation program we performed a qPCR evaluating the 
expression of well-recognized differentiation markers such as Osterix, Sparc, Spp1, 
Bglap, Runx2 and Ppar-g on TNF and IFN-γ stimulated cells. We demonstrated that 
TNF reduced Osterix, Sparc, Spp1, Bglap and Ppar-g and IFN-γ down-modulated the 
expression of Osterix, Runx2, Sparc and Spp1 but not Bglap and Ppar-g (Figure 30E).  
The combination of TNF and IFN-γ was additive in decreasing the expression of Spp1 










Figure 30 – CD40 expression is induced by pro-inflammatory cytokines and is associated 
with the acquisition of immune regulatory features - A. Frequency of CD4+ and CD8+ in 
WT irradiated mice B. Frequency of Teff (CD4+Foxp3-) and Treg (CD4+Foxp3+) within the 
BM of WT irradiated mice C. Frequency of CD4+ cells producing TNF and IFN-γ within the 
BM of irradiated mice D. CD40 expression on BM-isolated MSCs (24h stimulation: IFN-




4day stimulation: GMCSF 40 ng/ml; IL-6 40 ng/ml; 7 day stimulation: IL-17 100 ng/ml; 
TGFβ 5ng/ml); E. qPCR evaluation the expression of osteogenic and adipogenic lineage in 
MSCs stimulated with IFN-γ (10 ng/ml) and TNF (50 ng/ml) for 24h. Results are expressed as 
mean± SD, *p< 0.05; **p< 0.01; ***p<0.001; ****p<0.0001 
 
 
4.2.2 CD40 stromal expression instructs BM microenvironment via OX40L 
 
Since we have demonstrated that CD40 expression can be induced by soluble factors 
release within the BM-microenvironment, we therefore verified whether the lack of 
CD40 expression could generate a pro-inflammatory microenvironment due to the 
impairment of Treg differentiation.  
To this end, we analysed BM T-cell status in WT> Cd40-KO and WT>WT chimeras, 4 
weeks after BMT showing that Tregs were reduced in the BM of WT> Cd40-KO 
chimeras compared to the WT>WT counterpart (Figure 31A), and IFNγ-producing Teff 
cells were significantly increased (Figure 31B,C).  
Considering the strong T-cell activation at the expense of Treg observed in the CD40-
KO recipients we evaluated the expression of OX40L, a co-stimulatory molecule 
involved in cytokine production, T-cell expansion, survival and memory development 
that has also been demonstrated to inhibit Treg differentiation as far as their suppressive 
activity 216,217. 
We evaluated Ox40l expression in Cd40-KO and wt BM-MSCs. IHC analysis 
performed on BM biopsies comparing the different mouse chimeras showed an overall 
increase in ox40l expression in Cd40-KO recipient mice (Figure 31D). 
The mechanisms that are able to modulate the expression of OX40L are particularly 
studied in B cells and DCs were only CD40 triggering is able to induce OX40L, while 
little is known for MSCs. To unveil the mechanisms underscoring ox40l expression in 
BM-MSCs, we stimulated BM-derived DCs and BM-MSCs with the CD40-agonist 
mAb CD40 (to trigger CD40) but also with pro-inflammatory cytokine TNF and IFN-γ.  
We demonstrated that, accordingly to the literature, DC up-regulates Ox40l only upon 
CD40 triggering, while pro-inflammatory cytokines did not induce any changes. 
(Figure 31E). Conversely in BM-MSCs also TNF was able to up-regulates Ox40l, 
independently from CD40 triggering (Figure 31E).  Most notably this induction was 
reduced by CD40 triggering, indicating an opposite effect of CD40 triggering on Ox40l 




In line RT-PCR analysis performed onto ex-vivo stimulated BM-MSCs showed that 
Cd40-KO BM-MSCs had higher Ox40l levels than their WT counterparts in response to 

































































































































































































Figure 31 – CD40 deficiency on BM-MSC is associated with a decreased frequency of Treg 




mice B. Frequency of CD4+ cells producing IFN-γ  within the BM of transplanted mice C. 
Representative dot plot showing IFN-γ production by CD4+ cells comparing wt and CD40-ko 
recipient mice. D. IHC analysis showing Ox40l expression in the BM of transplanted wt and 
Cd40-KO. Upper panels 10X magnification; Panels below 20X magnification E. ox40l 
expression in BM-MSCs stimulated with IFN-γ 10 ng/ml, TNF 50 ng/ml and aCD40 mAb or 
isotype control (5µg/ml) for 24h F. Ox40l expression in wt and Cd40-KO BM-MSCs stimulated 
with IFN-γ 10 ng/ml, TNF 50 ng/ml for 24h. Results are expressed as mean± SD, *p< 0.05; 
**p< 0.01; ***p<0.001; ****p<0.0001 
 
 
4.2.3 Altered B-cell lymphopoiesis in the BM is a characteristic of Cd40-KO 
recipient chimeric mice 
 
To assess whether Cd40 deficiency can impact on long term reconstitution we set up 
BMT experiments in which recipient mice, either WT or Cd40-KO were lethally 
irradiated and transplanted with HSCs from congenic WT donors. Twenty-one days 
post-BMT, FACS analysis on PB, BM, and spleens of recipient mice was performed. In 
the PB (Figure 32A), Cd40-KO recipients compared with WT mice showed a 
significant reduction in the frequency of B220+ B-cells and of CD3+ T-cells. In line 
with the PB analysis, we also observed a reduction of B220+ cells in the BM of Cd40-
KO recipients (Figure 32B). Particularly, B-cell development was largely defective, as 
shown by the reduced B220+CD43+ and almost absent B220+CD43- fractions (Figure 
32B). B-cell development was arrested at the A and B fractions, which correspond to 
the pre-pro-B and early pro-B phases, respectively, with reduced development of the 
fraction of C’-C precursors (late pro-B and large pre-B) (Figure 32C). Interestingly, 
also in the spleens of Cd40-KO recipients we noted an overall decrease of 
B220+frequency compared with WT mice (Figure 32D) suggesting that CD40 
expression in radio-resistant cells is necessary to allow proper BM B- cell development, 









Figure 32 – Analysis of B-cell development in WT>WT and WT>Cd40-KO BM chimeras. 
A. Cumulative data of PB FACS analysis showing the frequencies of B220+ and CD3+ cells in 
the PB of WT>Cd40-KO compared to WT>WT BM chimeras. B. Cumulative FACS analysis of 
the BM showing the overall decrease in B220+, B220+CD43+ and B220+CD43- B-cell subsets 
in Cd40-KO recipients C. Cumulative data showing the frequency of pre-pro-B and early pro-B 
precursors (A and B fractions), and of late pro-B and large pre-B precursors (C’-C) in chimeric 
mice; D. Frequency of B220+ B-cells in the spleen of Cd40-KO compared with WT mice. 





5. DISCUSSION  
 
This study demonstrates the role of ZEB-1, when expressed by leukemic blasts, and of 
CD40, when expressed by BM-MSCs, in promoting the immunosuppressive 
environment sustaining AML development and more in general immune suppression in 
the BM niche. 
The establishment of immune suppression have been extensively characterized in solid 
tumors and depends on the recruitment of specific immune cell types (Treg and 
MDSCs), the engagement of inhibitory T-cells pathways (i.e. PD-L1-/PD-1) and the 
interference with specific metabolic pathways such as IDO-1 218,219. All these 
mechanisms, although less characterized, could be potentially involved in AML 
immune escape, either through a blast-autonomous mechanism or through the 
engagement of bystander cells, like MSCs.  
Here, we unveiled for the first time the role of ZEB-1 not only as a regulator of AML 
invasiveness, but also as a key orchestrator of the AML immunosuppressive 
environment.  
Our data are in line with the literature and also extend previous results obtained in AML 
with complex Kariotype, to CN-AML and pointed out that the poor outcome of ZEB1+ 
AML could be the consequence of the immunosuppressive and self-maintaining 
microenvironment initiated by ZEB1.  
Even if the majority of the studies agree in recognize ZEB1 as an oncogene in AML, a 
recent study performed by Almotiri A et al postulated that Zeb1 acts as a transcriptional 
regulator in haematopoiesis and its expression is required to suppress leukemic potential 
in AML 220. Indeed, analysing the overall expression of ZEB-1 in public datasets the 
authors found that ZEB-1 expression was lower in AML patients compared with healthy 
controls, thus implicating Zeb-1 as a tumor suppressor in AML.  
We explained these apparent paradoxical results performing immunohistochemistry 
analysis and evaluating not only the expression of ZEB-1 at transcript level, but also its 
protein expression using AML patients BM biopsies. Notably, we found that CN AML 
patients display an intra-patient variable expression of ZEB1 and are characterized by 
the presence of ZEB1+ and ZEB1neg blasts. Although this finding deserves further 
investigations, our result seems to suggest that in CN AML, where the expression of 




those AML clones displaying more aggressive features that could be responsible for 
patients relapse and can impact on chemotherapy response. Given these data, for the 
analysis of public datasets, to better describe the complex scenario occurring within the 
BM of AML patients, we decided to divide patients without considering the overall 
expression of ZEB1, while separating AML patients in two groups and identifying those 
patients expressing high levels of ZEB1 and those cases characterized by a low/negative 
expression.  
We found that ZEB-1 expression defined a subgroup of AML patients (termed Zeb-
1high) with a peculiar T-cell microenvironment enriched in IL-17+ T-cells. GEP analysis 
associated ZEB-1 expression to those of other immune regulatory genes, including PD-
L1 and CD40.   
To unveil the real contribution of ZEB-1 in shaping the BM T cell microenvironment, 
we designed ad hoc murine models knocking down ZEB-1 in the C1498 leukemia cell 
line. The injection of C1498 cell stable silenced for ZEB-1 expression, was associated 
with a significant reduction in tumour take, which was paralleled by a strong 
modification of BM T-cells.  We found a reduction of exhausted lymphocytes along 
with an expansion of cytotoxic CD8+ T cells. Notably, these changes in the CD8 cells 
were associated to the decrease of IL-17A+ CD4+ and, more interestingly, IL-17A+ 
Tregs. Since it has been shown that TGF-β, IL-6, IL-23, and IL-1β are required for 
Th17 development and for the differentiation of Treg cells into IL-17A-producing 
Th17-like Treg cells (as reviewed in 221,222), we evaluated whether our AML cells were 
able to produce these cytokines. Interestingly, in C1498 cell lines, Zeb-1 
downregulation was associated with the reduced expression of Tgf-β, Il-6 and Il-23, 
suggesting that the decrease production of such molecules by leukemic cells within the 
BM of mice injected with silenced C1498 could be responsible for the reduction in 
Th17 cells.  
Backing to humans, the analysis of AML patients before and after chemotherapy 
showed and increased expression of ZEB-1 at relapse and this was associated with an 
enrichment of Th17 pathways, highlighting that the increase of IL-17 production can be 
considered as a relevant feature directly associated with ZEB-1 levels.  
The relevance of IL-17A produced by Th17 cells in AML progression has not been 
fully elucidated. Indeed, only few studies have shown the effects of the reduced IL-17A 
levels in patients, mainly highlighting its impact on the prognosis. In particular, high 




increased proliferation of leukemic cells 133. In line with these evidence coming from 
the literature, we also showed that IL-17A treatment was able to limit the proliferation 
of Zeb-1 silenced C1498, while the stimulation of parental cells was associated with an 
enhanced growth. More interestingly, IL-17A treatment of C1498-Scr cells up-regulated 
the expression of Socs2 and Mef2c, two molecules the have been reported to be 
associated with stemness and with a more aggressive phenotype 213,214.  
Overall, our data support that ZEB1 could be a biomarker of AML aggressiveness able 
to identify patients with a worse prognosis.  
Strengthening the role of ZEB-1 in immune suppression we showed for the first that 
AML blasts can directly suppress T-cell proliferation and that knocking down ZEB-1 
reduced this capacity. 
Reasons for such a reduction can be found in the capacity of ZEB-1 to directly regulate 
the expression of Arg-1 an enzyme crucial in suppressing CD4 and CD8 T-cell 
proliferation 223. In the AML context, Mussai et al have demonstrated that arg-2 
expressed by blasts is able to inhibit T-cell proliferation in vitro creating the 
immunosuppressive microenvironment that allow leukemia progression 224. The 
possibility that ZEB1 directly regulate the immune suppressive capacity of blasts was 
supported our additional findings showing that ZEB1 silencing in neutrophils isolated 
from lung cancer patients was associated with ARG-1 reduction and decreased levels of 
PD-L1 and TGF-β.  
Noteworthy, as demonstrated by Stavropoulou et al using an MLL/AF9-driven mouse 
model 184, also in our study Zeb-1 expression in leukemic cells negatively impacts on 
patients’ overall survival, with Zeb-1 expression clearly associated with poor outcome. 
Accordingly, in mouse models, Zeb-1 expression was associated with enhanced 
invasive abilities in vitro and in vivo. Mice injected with Zeb-1 expressing cells 
displayed increased hepatic metastatic areas compared with those injected with silenced 
cells, a phenotype that might depends on the capacity of ZEB-1 to directly regulate 
Mmp-9 expression.  
Overall, these data unveiled new activities of ZEB1 in conferring tumor aggressiveness 
along leukemia onset and progression.  These activities include the induction of Th17 
cells that directly support tumour proliferation and aggressiveness, via IL17. Our results 
should promote ZEB1 as biomarker useful to identify CN-AML patients with most 
aggressive disease and offer new therapeutic options, also including immunotherapy, 




Along with immune cells, also MSCs play a crucial role in supporting AML 
development. In this context, BM-MSCs are able to inhibit the T-cells and B-cells 
proliferation or to impair NK cell functions and DC maturation and induce a tolerogenic 
environment 225. Moreover, in vivo administration of MSCs is able to treat acute 
GVHD, and/or to prevent its occurrence in the human bone marrow transplant setting, 
highlighting the immunomodulatory properties of MSCs 226,227. Our lab demonstrated 
that CD40 expressed by MSCs of splenic marginal zone lymphoma patients play a 
crucial role in sustaining tumor cell growth establishing a cross-talk with mast cells 201. 
We therefore hypothesized that also in AML patients CD40 expression on stromal cells 
can be relevant in shaping BM tolerance during leukemia. 
GEP analysis showed a variable expression of CD40 in AML patients. This result was 
also confirmed at protein level in a small cohort of AML patients, where we found that 
CD40 levels were overall increased in AML patients compared with a healthy control, 
The expression was again variable, either on stromal meshwork or confined at leukemic 
cells, suggesting that leukemic blast intrinsic features could influence CD40 levels on 
MSCs.  
Accordingly, MSCs isolated from mice injected with C1498-Scr expressed higher levels 
of Cd40 compared not only with control mice, but also with mice injected with silenced 
cells, pointing out a possible relationship between Zeb-1 and Cd40 that deserves more 
studies. Moreover, Cd40 expression was also associated with enhanced levels of Ido-1 
and Il-6, confirming that the expression of Zeb-1 in leukemic blasts influences the 
immune-modulatory properties of BM-MSCs, in turn promoting a favourable 
microenvironment for AML growth.  
Given this preliminary evidence, we hypothesized that the induction of an 
immunosuppressive microenvironment could be driven or by cell-autonomous 
mechanism (mainly regulated by Zeb-1 expression on leukemic cells) or by the 
engagement of mesenchymal bystander cells, that, through the up-regulation of CD40 
could generate a tolerogenic microenvironment influencing T-cell status.  To disclose 
the immunomodulatory role of CD40 expressed by MSCs, we set-up hematopoietic 
stem cells transplantation experiments, since we considered this setting the most 
representative condition that could force the need of homeostatic signals to prevent a 
pathological and unwanted T cell activation. We demonstrated that Cd40 expression on 
MSCs is finely regulated within the bone marrow and in particular it is induced by pro-




cytokines such TNF-α and IFN-γ. Along with Cd40, we also observed the increase of 
other immune-modulatory molecules (Pd-l1, Il-2, Nos2) and the concomitant down-
regulation of genes involved in the differentiation towards osteoblast or adipocytes. 
These results suggest that the acquisition of Cd40 could mirror the acquisition of a 
peculiar immunosuppressive MSC phenotype and the gain of immune-regulatory 
features at the expense of the canonical structural properties by MSCs that, in particular 
conditions, are crucial for the maintenance and also the retrieval of the BM-proper 
homeostasis influencing T-cell activation. Indeed, for our hypothesis, it is expected that 
T cells can be influenced by MSCs but, we can also assume that some cytokines 
released by T cells can influence MSCs and, in particular, CD40 induction. In this 
context, our results underline that upon irradiation, the up-regulation of Cd40 on BM-
MSC is associated with a decreased frequency of Treg and with a concomitant increase 
of Teffector cells producing type I cytokines, including TNF-α and IFN-γ,  that, as 
discussed before, are the two major cytokines responsible for Cd40 induction on 
MSCs. 	Hence, the increased of Cd40 levels in radio-resistant BM-MSCs is required to 
restore the BM homeostatic conditions preventing the persistent activation of T-cells. 
Indeed, in the absence of stromal CD40, Tregs were reduced in favour of pro-
inflammatory Teff. Molecularly, this was associated with an increased production of 
Ox40l by MSCs upon pro-inflammatory cytokine stimulation. Ox40l has been reported 
to suppress Treg activity and inhibits the generation of new Tregs 216,217,228, being 
crucial for the increase of activated T-cells. In this context, it has been shown that, since 
OX40 receptor is transiently induced on activated naive CD4 and CD8 T cells, OX40L 
can represent an additional mechanism to further amplify T cell responsiveness 
(reviewed in 229). The same mechanisms described above could be also in place during 
leukemia development. Indeed, a preliminary experiment showed a higher percentage of 
C1498-GFP+ cells not only in the BM, but also in the spleen and liver of WT mice 
compared with the Cd40-Ko counterpart, pointing out the relevance of CD40 in the 
induction of an immunosuppressive microenvironment needed for AML take and 
dissemination.  
 
Taken together, our results shed a new light on the contribution of BM 
microenvironment in the AML development and progression pointing out the crucial 




hematological malignancies. These findings suggested that Zeb-1 can be considered as a 
biomarker able to identify a particular subset of aggressive AML that is characterized 
by a peculiar immunosuppressive bone marrow microenvironment. Novel approaches 
able to down-regulate Zeb-1 levels are needed. Moreover, a better characterization of 
the bone marrow microenvironment and the molecular drivers that are involved in AML 
development and progression could help to identify novel personalized therapeutic 
strategies that can not only target leukemic cells but can also interfere with the 
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